Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.7.1.2 - glucokinase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acquired Immunodeficiency Syndrome
Recent Developments in Medicinal Chemistry of Allosteric Activators of Human Glucokinase for Type 2 Diabetes Mellitus Therapeutics.
Adenoma, Islet Cell
Defective regulation of glucokinase in rat pancreatic islet cell tumours.
Anemia
[Leading criteria of reticulocyte maturation. 3. Behavior of hexokinase and glucokinase of red blood cells during a bleeding anemia of the rabbit]
Anemia, Megaloblastic
Neonatal Diabetes Mellitus: Novel Mutations.
Atherosclerosis
Hyperglycemia Induced by Glucokinase Deficiency Accelerates Atherosclerosis Development and Impairs Lesion Regression in Combined Heterozygous Glucokinase and the Apolipoprotein E-Knockout Mice.
Pre-germinated brown rice extract ameliorates high-fat diet-induced metabolic syndrome.
The APOE?3-Leiden Heterozygous Glucokinase Knockout Mouse as Novel Translational Disease Model for Type 2 Diabetes, Dyslipidemia, and Diabetic Atherosclerosis.
Breast Neoplasms
Molecular and disease association of gestational diabetes mellitus affected mother and placental datasets reveal a strong link between insulin growth factor (IGF) genes in amino acid transport pathway: A network biology approach.
Brucellosis
Studies on recombinant glucokinase (r-glk) protein of Brucella abortus as a candidate vaccine molecule for brucellosis.
Burkitt Lymphoma
Characterization of colorectal-cancer-related cDNA clones obtained by subtractive hybridization screening.
Carcinogenesis
First evidence of changes in enzyme kinetics and stability of glucokinase affected by somatic cancer-associated variations.
[CHANGES IN GLUCOKINASE AND HEXOKINASE CONTENT OF THE RAT LIVER AFTER FASTING, DURING CARCINOGENESIS AND IN PRIMARY AND TRANSPLANTED HEPATOMA.]
Carcinoid Tumor
Thymic Carcinoid as the First Manifestation of Multiple Endocrine Neoplasia Type 1 Syndrome: A Case Report and Review of the Literature.
Carcinoma
Carbohydrate metabolism in human renal clear cell carcinomas.
Isoenzyme shift from glucokinase to hexokinase is not an early but a late event in hepatocarcinogenesis.
Carcinoma, Hepatocellular
A case of minimal deviation hepatoma in man with elevated liver-type pyruvate kinase isozyme.
A hexokinase isoenzyme switch in human liver cancer cells promotes lipogenesis and enhances innate immunity.
Alteration of enzyme function of the type II hexokinase C-terminal half on replacements of restricted regions by corresponding regions of glucokinase.
Characterization of the 5' flanking region of rat glucokinase gene.
Glucokinase expression in rat hepatoma cells induces glucose uptake and is rate limiting in glucose utilization.
Hepatic glycogen synthesis in the absence of glucokinase: the case of embryonic liver.
Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin.
Identification of upstream stimulatory factor as transcriptional activator of the liver promoter of the glucokinase gene.
Induction of glucokinase mRNA by dietary phenolic compounds in rat liver cells in vitro.
Liver glycogen synthase but not the muscle isoform differentiates between glucose 6-phosphate produced by glucokinase or hexokinase.
Liver-specific enhancer of the glucokinase gene.
The promoter for the gene encoding the catalytic subunit of rat glucose-6-phosphatase contains two distinct glucose-responsive regions.
[Activity of enzymes of glycolysis and gluconeogenesis in primary hepatomas induced by diethylnitrosamine]
[Activity of the key glycolysis and respiration enzymes in the rat liver in chemical carcinogenesis]
[Biochemical features of the liver of high and low cancer mouse strains and primary spontaneous hepatomas]
[CHANGES IN GLUCOKINASE AND HEXOKINASE CONTENT OF THE RAT LIVER AFTER FASTING, DURING CARCINOGENESIS AND IN PRIMARY AND TRANSPLANTED HEPATOMA.]
[Noradrenaline and glycogen content and the activity of several enzymes of carbohydrate metabolism in normal, embryonic, and partly denervated livers and in hepatomas of the rat]
[Some characteristics of isoenzymic spectrum of hexokinase and glucose levels in hepatomas and liver of the host]
Chagas Disease
A Mechanistic Probe into the Dual Inhibition of T. cruzi Glucokinase and Hexokinase in Chagas Disease Treatment - A Stone Killing Two Birds?
Structure-based approach to the identification of a novel group of selective glucosamine analogue inhibitors of Trypanosoma cruzi glucokinase.
Colonic Neoplasms
Genetic approaches to common diseases.
Colorectal Neoplasms
Genetic Variants, Prediagnostic Circulating Levels of Insulin-like Growth Factors, Insulin, and Glucose and the Risk of Colorectal Cancer: The Multiethnic Cohort Study.
Coma
Effect of total hepatectomy on selected cerebral substrates and enzymes of the glycolytic pathways and Krebs cycle.
Congenital Hyperinsulinism
A report of 2 new cases of MODY2 and review of the literature: Implications in the search for type 2 Diabetes drugs.
Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation.
Cell-specific roles of glucokinase in glucose homeostasis.
Clinical and enzymatic phenotypes in congenital hyperinsulinemic hypoglycemia due to glucokinase-activating mutations: A report of two cases and a brief overview of the literature.
Conformational transition pathway in the activation process of allosteric glucokinase.
Conformational transition pathway in the allosteric process of human glucokinase.
Diagnostic difficulties in glucokinase hyperinsulinism.
Evidence-based tailoring of bioinformatics approaches to optimize methods that predict the effects of nonsynonymous amino acid substitutions in glucokinase.
Familial hyperinsulinism caused by an activating glucokinase mutation.
Glucokinase mutation-a rare cause of recurrent hypoglycemia in adults: a case report and literature review.
Hyperinsulinism in infancy and childhood: when an insulin level is not always enough.
Lys169 of human glucokinase is a determinant for glucose phosphorylation: implication for the atomic mechanism of glucokinase catalysis.
Mechanisms of Disease: advances in diagnosis and treatment of hyperinsulinism in neonates.
Mechanistic Origins of Enzyme Activation in Human Glucokinase Variants Associated with Congenital Hyperinsulinism.
Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation.
Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in ? cells.
[Hyperinsulinism in infancy and childhood: when an insulin level is not always enough.]
Coronary Artery Disease
Association of GCKR Gene Polymorphisms with the Risk of Nonalcoholic Fatty Liver Disease and Coronary Artery Disease in a Chinese Northern Han Population.
Cardiovascular risk assessment by coronary artery calcium score in subjects with maturity-onset diabetes of the young caused by glucokinase mutations.
G(-30)A polymorphism in the pancreatic promoter of the glucokinase gene associated with angiographic coronary artery disease and type 2 diabetes mellitus.
Polymorphisms in the GCKR are associated with serum lipid traits, the risk of coronary artery disease and ischemic stroke.
Diabetes Complications
Diabetes complications in NIDDM kindreds linked to the MODY3 locus on chromosome 12q.
Identification of Maturity-Onset Diabetes of the Young Caused by Glucokinase Mutations Detected Using Whole-Exome Sequencing.
Diabetes Mellitus
A case-control study and meta-analysis confirm glucokinase regulatory gene rs780094 is a risk factor for gestational diabetes mellitus.
A De Novo Whole GCK Gene Deletion Not Detected by Gene Sequencing, in a Boy with Phenotypic GCK Insufficiency.
A family with novel homozygous deletion mutation (c.1255delT; p.Phe419Serfs*12) in the glucokinase gene, which is a rare cause of permanent neonatal diabetes mellitus.
A genetic marker at the glucokinase gene locus for type 2 (non-insulin-dependent) diabetes mellitus in Mauritian Creoles.
A glucokinase gene mutation in a young boy with diabetes mellitus, hyperinsulinemia, and insulin resistance.
A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria.
A new compound heterozygosis for inactivating mutations in the glucokinase gene as cause of permanent neonatal diabetes mellitus (PNDM) in double-first cousins.
A patent review of glucokinase activators and disruptors of the glucokinase--glucokinase regulatory protein interaction: 2011-2014.
A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study).
Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model.
Association between lncRNA and GCKR gene in type 2 diabetes mellitus.
Author Correction: Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus.
Characterization of a third simple tandem repeat polymorphism in the human glucokinase gene.
Characterization of Japanese families with early-onset type 2 (non-insulin dependent) diabetes mellitus and screening for mutations in the glucokinase and mitochondrial tRNA(Leu(UUR)) genes.
Comment on Rudland et al. Identifying Glucokinase Monogenic Diabetes in a Multiethnic Gestational Diabetes Mellitus Cohort: New Pregnancy Screening Criteria and Utility of HbA1c. Diabetes Care 2016;39:50-52.
Comparison of the circulating metabolite profile of PF-04991532, a hepatoselective glucokinase activator, across preclinical species and humans: potential implications in metabolites in safety testing assessment.
Diabetes mellitus and glucokinase.
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
Discovery of a novel phenylethyl benzamide glucokinase activator for the treatment of type 2 diabetes mellitus.
Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus.
Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation.
Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
Dose-Dependent Effect of Piragliatin, a Glucokinase Activator, on the QT Interval Following Short-Term Multiple Doses in Patients With Type 2 Diabetes Mellitus.
Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus.
Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin.
Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase.
Early-onset type 2 (non-insulin-dependent) diabetes mellitus is associated with glucokinase locus, but not with adenosine deaminase locus, in the Japanese population.
Early-onset Type II diabetes mellitus in Italian families due to mutations in the genes encoding hepatic nuclear factor 1 alpha and glucokinase.
Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus.
Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus.
Efficacy and safety of glucokinase activators for type 2 diabetes mellitus therapy: a meta-analysis of double-blind randomized controlled trials.
Essential role of glucokinase in the protection of pancreatic ? cells to the glucose energetic status.
Ethnopharmacological perspectives of glucokinase activators in the treatment of diabetes mellitus.
Familial adult onset hyperinsulinism due to an activating glucokinase mutation: implications for pharmacological glucokinase activation.
Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus.
Four novel cases of permanent neonatal diabetes mellitus caused by homozygous mutations in the glucokinase gene.
G(-30)A polymorphism in the pancreatic promoter of the glucokinase gene associated with angiographic coronary artery disease and type 2 diabetes mellitus.
Genetic causes of maturity onset diabetes of the young may be less prevalent in American pregnant women recently diagnosed with diabetes mellitus than in previously studied European populations.
GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?
Glucokinase and candidate genes for type 2 (non-insulin-dependent) diabetes mellitus.
Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes.
Glucokinase gene in gestational diabetes mellitus: population association study and molecular scanning.
Glucokinase gene mutations: structural and genotype-phenotype analyses in MODY children from South Italy.
Glucokinase mutations associated with non-insulin-dependent (type 2) diabetes mellitus have decreased enzymatic activity: implications for structure/function relationships.
Glucokinase mutations, insulin secretion, and diabetes mellitus.
Glucokinase, glucose homeostasis, and diabetes mellitus.
Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study.
High prevalence of a missense mutation of the glucokinase gene in gestational diabetic patients due to a founder-effect in a local population.
High prevalence of glucokinase mutations in Italian children with MODY. Influence on glucose tolerance, first-phase insulin response, insulin sensitivity and BMI. Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetes (SIEDP).
Human glucokinase gene: isolation, characterization, and identification of two missense mutations linked to early-onset non-insulin-dependent (type 2) diabetes mellitus.
Human islet glucokinase gene. Isolation and sequence analysis of full-length cDNA.
Human pancreatic beta-cell glucokinase: cDNA sequence and localization of the polymorphic gene to chromosome 7, band p 13.
Hybrid of 1-deoxynojirimycin and polysaccharide from mulberry leaves treat diabetes mellitus by activating PDX-1/insulin-1 signaling pathway and regulating the expression of glucokinase, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase in alloxan-induced diabetic mice.
Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families.
Identification of glucokinase mutation in subjects with post-renal transplantation diabetes mellitus.
Identification of glucokinase mutations in subjects with gestational diabetes mellitus.
Identification of YH-GKA, a novel benzamide glucokinase activator as therapeutic candidate for type 2 diabetes mellitus.
Importance of glucokinase -258G/A polymorphism in Asian Indians with post-transplant and type 2 diabetes mellitus.
In vivo anti-diabetic, antioxidant and molecular docking studies of 1, 2, 8-trihydroxy-6-methoxy xanthone and 1, 2-dihydroxy-6-methoxyxanthone-8-O-?-D-xylopyranosyl isolated from Swertia corymbosa.
Interleukin-1 reduces the glycolytic utilization of glucose by pancreatic islets and reduces glucokinase mRNA content and protein synthesis by a nitric oxide-dependent mechanism.
Lack of Potential Pharmacokinetic and Pharmacodynamic Interactions Between Piragliatin, a Glucokinase Activator, and Simvastatin in Patients With Type 2 Diabetes Mellitus.
Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition: Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD.
Linkage analysis does not support a role for glucokinase gene in the aetiology of type 2 diabetes mellitus among north western Italians.
Linkage analysis of the glucokinase locus in familial type 2 (non-insulin-dependent) diabetic pedigrees.
LncRNA NONRATT021972 siRNA normalized the dysfunction of hepatic glucokinase through AKT signaling in T2DM rats.
Maturity Onset Diabetes of the Young due to Glucokinase, HNF1-A, HNF1-B, and HNF4-A Mutations in a Cohort of Turkish Children Diagnosed as Type 1 Diabetes Mellitus.
Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: a sequestration mechanism in metabolic regulation.
Mild fasting hyperglycemia in children: high rate of glucokinase mutations and some risk of developing type 1 diabetes mellitus.
Modulation of Glucokinase Regulatory Protein: A Double-Edged Sword?
Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict Protein-Ligand Residence Times.
Molecular genetics of diabetes mellitus in Chinese subjects: identification of mutations in glucokinase and hepatocyte nuclear factor-1alpha genes in patients with early-onset type 2 diabetes mellitus/MODY.
Molecular screening of the glucokinase gene in familial type 2 (non-insulin-dependent) diabetes mellitus.
Mutations in pancreatic ß-cell Glucokinase as a cause of hyperinsulinaemic hypoglycaemia and neonatal diabetes mellitus.
Mutations in the glucokinase gene are not a major cause of late-onset type 2 (non-insulin-dependent) diabetes mellitus in Japanese subjects.
Mutations of the human glucokinase gene and diabetes mellitus.
Neonatal diabetes mellitus due to complete glucokinase deficiency.
New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
NIDDM--genetic marker; glucose transporter, glucokinase, and mitochondria gene.
Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.
Ordered Conformation-Regulated Vesicular Membrane Permeability.
Overexpression of a glucokinase point mutant in the treatment of diabetes mellitus.
Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose.
Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: initial response to oral sulphonylurea therapy.
Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study.
Polymorphism of glucokinase gene in non-insulin dependent diabetes mellitus.
Polymorphisms in the GCK gene increase the risk of clopidogrel resistance in stable coronary artery disease (SCAD) patients.
Polymorphisms rs144723656, rs2268574, and rs2268575 of the glucokinase gene are not associated with obese women with type 2 diabetes mellitus.
Positive association in the absence of linkage suggests a minor role for the glucokinase gene in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus amongst south Indians.
Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus.
Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif.
Raised blood glucose due to heterozygous glucokinase gene mutation (GCK-MODY) diagnosed for the first time in pregnancy: The dilemmas and successful management - Case report and review of literature.
Recent clinical advances of glucokinase activators in the treatment of diabetes mellitus type 2.
Recent Developments in Medicinal Chemistry of Allosteric Activators of Human Glucokinase for Type 2 Diabetes Mellitus Therapeutics.
Recent Updates on Glucokinase Activators and Glucokinase Regulatory Protein Disrupters for the Treatment of Type 2 Diabetes Mellitus.
Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus.
Repair of diverse diabetic defects of ?-cells in man and mouse by pharmacological glucokinase activation.
Routine mutation screening of HNF-1alpha and GCK genes in MODY diagnosis: how effective are the techniques of DHPLC and direct sequencing used in combination?
Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.
Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study.
Screening of mutations and polymorphisms in the glucokinase gene in Czech diabetic and healthy control populations.
Screening of mutations in the GCK gene in Jordanian maturity-onset diabetes of the young type 2 (MODY2) patients.
Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase.
Structural instability of mutant beta-cell glucokinase: implications for the molecular pathogenesis of maturity-onset diabetes of the young (type-2).
The beta cell glucokinase promoter variant is an unlikely risk factor for diabetes mellitus. Diabetes Incidence Study in Sweden (DISS).
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus.
The effects and safety of activators of glucokinase versus placebo in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
The efficacy and safety of glucokinase activators for the treatment of type-2 diabetes mellitus: A protocol for systematic review and meta-analysis.
The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food.
The glucokinase mutation p.T206P is common among MODY patients of Jewish Ashkenazi descent.
The population association of glucokinase gene with type 2 (noninsulin-dependent) diabetes mellitus in Chinese.
Three novel missense mutations in the glucokinase gene (G80S; E221K; G227C) in Italian subjects with maturity-onset diabetes of the young (MODY). Mutations in brief no. 162. Online.
Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp.
Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn-Research-Confirm Process.
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
Two microsatellite repeat polymorphisms flanking opposite ends of the human glucokinase gene: use in haplotype analysis of Welsh Caucasians with type 2 (non-insulin-dependent) diabetes mellitus.
Type 2 (non-insulin-dependent) diabetes mellitus associated with a mutation of the glucokinase gene in a Japanese family.
Variability in the age at diagnosis of diabetes in two unrelated patients with a homozygous glucokinase gene mutation.
[Clinical studies on the serum glucokinase activity values. 1. Erythrocyte glucokinase activity values in normal infants and children, in ekiri-like syndrome, in diabetes mellitus, and in liver diseases.]
[Diabetes susceptibility genes]
[Glucokinase gene mutations in gestational diabetes in Polish population. Prediction of diabetes mellitus development after delivery]
[Salicylic acid derivatives as simplified and novel GK small molecule activators].
Diabetes Mellitus, Experimental
[Incorporation of S35 labelled methionine in the liver proteins of rats with alloxan diabetes in conditions of block or "circumvention" of the glucokinase reaction.]
Diabetes Mellitus, Type 1
Adenovirus-mediated expression of glucokinase in the liver as an adjuvant treatment for type 1 diabetes.
An evolving spectrum of diabetes in a woman with GCK-MODY.
Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations.
Circulating ghrelin level is higher in HNF1A-MODY and GCK-MODY than in polygenic forms of diabetes mellitus.
Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.
High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes.
Lack of association between type 1 diabetes and the glucokinase gene.
Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level.
Linkage and association between insulin-dependent diabetes mellitus (IDDM) susceptibility and markers near the glucokinase gene on chromosome 7.
Lower Circulating miR-122 Level in Patients with HNF1A Variant-Induced Diabetes Compared with Type 2 Diabetes.
Maturity Onset Diabetes of the Young due to Glucokinase, HNF1-A, HNF1-B, and HNF4-A Mutations in a Cohort of Turkish Children Diagnosed as Type 1 Diabetes Mellitus.
Mild fasting hyperglycemia in children: high rate of glucokinase mutations and some risk of developing type 1 diabetes mellitus.
Molecular and functional changes in glucokinase expression in the brainstem dorsal vagal complex in a murine model of type 1 diabetes.
Mutations in HNF1A Result in Marked Alterations of Plasma Glycan Profile.
Ordered Conformation-Regulated Vesicular Membrane Permeability.
Recovery of pancreatic beta cells in response to long-term normoglycemia after pancreas or islet transplantation in severely streptozotocin diabetic adult rats.
The beta cell glucokinase promoter variant is an unlikely risk factor for diabetes mellitus. Diabetes Incidence Study in Sweden (DISS).
The coexistence of type 1 diabetes, MODY2 and metabolic syndrome in a young girl.
The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes.
Therapy targeting beta-cell survival and function in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
A case-control study and meta-analysis confirm glucokinase regulatory gene rs780094 is a risk factor for gestational diabetes mellitus.
A Common Gene Variant in Glucokinase Regulatory Protein Interacts With Glucose Metabolism on Diabetic Dyslipidemia: the Combined CODAM and Hoorn Studies.
A Comprehensive Analysis of Hungarian MODY Patients-Part II: Glucokinase MODY Is the Most Prevalent Subtype Responsible for about 70% of Confirmed Cases.
A family with novel homozygous deletion mutation (c.1255delT; p.Phe419Serfs*12) in the glucokinase gene, which is a rare cause of permanent neonatal diabetes mellitus.
A gene for maturity onset diabetes of the young (MODY) maps to chromosome 12q.
A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria.
A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.
A missense mutation in the hepatocyte nuclear factor 4 alpha gene in a UK pedigree with maturity-onset diabetes of the young.
A missense mutation, Val62Ala, in the glucokinase gene in a Norwegian family with maturity-onset diabetes of the young.
A new clinical screening strategy and prevalence estimation for glucokinase variant-induced diabetes in an adult Chinese population.
A new missense mutation in the glucokinase gene in an Italian Mody family.
A new mouse model of type 2 diabetes, produced by N-ethyl-nitrosourea mutagenesis, is the result of a missense mutation in the glucokinase gene.
A novel glucokinase gene mutation and its effect on glycemic/C-peptide fluctuations in a patient with maturity-onset diabetes of the young type 2.
A novel heterozygous mutation in the glucokinase gene is responsible for an early-onset mild form of maturity-onset diabetes of the young, type 2.
A novel mutation in exon 5 of the glucokinase gene in an Argentinian family with maturity onset diabetes of the young.
A Novel Mutation of the Glucokinase Gene in Maturity-onset Diabetes of the Young Type 2 (MODY2).
A novel Phe75fsdelT mutation in the hepatocyte nuclear factor-4alpha gene in a Danish pedigree with maturity-onset diabetes of the young.
A panel of diverse assays to interrogate the interaction between glucokinase and glucokinase regulatory protein, two vital proteins in human disease.
A patent review of glucokinase activators and disruptors of the glucokinase--glucokinase regulatory protein interaction: 2011-2014.
A Pathophysiology of Type 2 Diabetes Unrelated to Metabolic Syndrome.
A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study).
A Rare Nonsense Mutation in the Glucokinase Regulator Gene Is Associated With a Rapidly Progressive Clinical Form of Nonalcoholic Steatohepatitis.
A review of maturity onset diabetes of the young (MODY) and challenges in the management of glucokinase-MODY.
A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
Abnormal regulation of hepatic glucose output in maturity-onset diabetes of the young caused by a specific mutation of the glucokinase gene.
Absence of Islet Autoantibodies and Modestly Raised Glucose Values at Diabetes Diagnosis Should Lead to Testing for MODY: Lessons From a 5-Year Pediatric Swedish National Cohort Study.
Additive activation of glucokinase by the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and the chemical activator LY2121260.
Agonist: the case for insulin resistance as a necessary and sufficient cause of type II diabetes mellitus.
Altered insulin secretory responses to glucose in subjects with a mutation in the MODY1 gene on chromosome 20.
AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes.
An evolving spectrum of diabetes in a woman with GCK-MODY.
An integrated view of beta-cell dysfunction in type-II diabetes.
Analysis of the GCK gene in 79 MODY type 2 patients: A multicenter Turkish study, mutation profile and description of twenty novel mutations.
Analysis of the glucokinase gene in Mexican families displaying early-onset non-insulin-dependent diabetes mellitus including MODY families.
Analysis of the glucokinase gene promoter in Japanese subjects with noninsulin-dependent diabetes mellitus.
Animal model for maturity-onset diabetes of the young generated by disruption of the mouse glucokinase gene.
Aptamer-based search for correlates of plasma and serum water T2: implications for early metabolic dysregulation and metabolic syndrome.
Assessing the potential of glucokinase activators in diabetes therapy.
Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model.
Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations.
Association between lncRNA and GCKR gene in type 2 diabetes mellitus.
Association of glucokinase regulatory protein polymorphism with type 2 diabetes and fasting plasma glucose: a meta-analysis.
Associations of common polymorphisms in GCKR with type 2 diabetes and related traits in a Han Chinese population: a case-control study.
ATP-sensitive K+ channel signaling in glucokinase-deficient diabetes.
Atypical phenotype associated with reported GCK exon 10 deletions: clinical judgement is needed alongside appropriate genetic investigations.
Author Correction: Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus.
Beta cell function and insulin sensitivity in obese youth with maturity onset diabetes of youth mutations vs type 2 diabetes in TODAY: Longitudinal observations and glycemic failure.
beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors.
beta-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1alpha and glucokinase mutations.
beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes.
Biochemical characterization of novel glucokinase mutations isolated from Spanish maturity-onset diabetes of the young (MODY2) patients.
Biophysical characterization of the interaction between hepatic glucokinase and its regulatory protein: impact of physiological and pharmacological effectors.
Bisphenol A impairs hepatic glucose sensing in C57BL/6 male mice.
C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.
CA-repeated microsatellite polymorphism of the glucokinase gene and its association with non-insulin-dependent diabetes mellitus in Taiwanese.
Candidate gene studies in pedigrees with maturity-onset diabetes of the young not linked with glucokinase.
Cardiovascular risk assessment by coronary artery calcium score in subjects with maturity-onset diabetes of the young caused by glucokinase mutations.
Cell-biological assessment of human glucokinase mutants causing maturity-onset diabetes of the young type 2 (MODY-2) or glucokinase-linked hyperinsulinaemia (GK-HI).
Cell-specific roles of glucokinase in glucose homeostasis.
Characterization of glucokinase mutations associated with maturity-onset diabetes of the young type 2 (MODY-2): different glucokinase defects lead to a common phenotype.
Characterization of glucokinase polymorphisms associated with maturity-onset diabetes of the young (MODY2) in Jordanian population.
Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes.
Characterization of two MODY2 mutations with different susceptibility to activation.
Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.
Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat.
Circulating ghrelin level is higher in HNF1A-MODY and GCK-MODY than in polygenic forms of diabetes mellitus.
Clinical characteristics of subjects with a missense mutation in glucokinase.
Clinical follow-up of two Brazilian subjects with glucokinase-MODY (MODY2) with description of a novel mutation.
Clinical implications of the glucokinase impaired function - GCK MODY today.
Clinically-Defined Maturity Onset Diabetes of the Young in Omanis: Absence of the common Caucasian gene mutations.
Cloning of cDNA and the gene encoding human hepatocyte nuclear factor (HNF)-3 beta and mutation screening in Japanese subjects with maturity-onset diabetes of the young.
Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus.
Co-localization of the ketohexokinase and glucokinase regulator genes to a 500-kb region of chromosome 2p23.
Common genetic variation in the glucokinase gene (GCK) is associated with type 2 diabetes and rates of carbohydrate oxidation and energy expenditure.
Common polymorphisms in MTNR1B, G6PC2 and GCK are associated with increased fasting plasma glucose and impaired beta-cell function in Chinese subjects.
Common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: a meta-analysis.
Common variants in maturity-onset diabetes of the young genes and future risk of type 2 diabetes.
Comparison of the circulating metabolite profile of PF-04991532, a hepatoselective glucokinase activator, across preclinical species and humans: potential implications in metabolites in safety testing assessment.
Complications of Diabetes: An Insight into Genetic Polymorphism and Role of Insulin.
Counterregulatory responses to hypoglycemia in patients with glucokinase gene mutations.
Crucial role of insulin receptor substrate-2 in compensatory beta-cell hyperplasia in response to high fat diet-induced insulin resistance.
Decreased expression of hepatic glucokinase in type 2 diabetes.
Deletion of the donor splice site of intron 4 in the glucokinase gene causes maturity-onset diabetes of the young.
Design, synthesis, and pharmacological evaluation of 2-(4-sulfonylphenyl)-2-[(E)-pyrrolidin-1-ylimino]-N-thiazoleacetamides as glucokinase activators.
Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators.
Detection of glucokinase gene defects in non-obese Japanese children diagnosed with diabetes by school medical examinations.
Determination of unbound fraction of dorzagliatin in human plasma by equilibrium dialysis and LC-MS/MS and its application to a clinical pharmacokinetic study.
Development of non-insulin-dependent diabetes mellitus in the double knockout mice with disruption of insulin receptor substrate-1 and beta cell glucokinase genes. Genetic reconstitution of diabetes as a polygenic disease.
Diabetes complications in NIDDM kindreds linked to the MODY3 locus on chromosome 12q.
Diabetes: from phenotypes to genotypes.
Diagnosis in diabetes: does it matter?
Diagnosis of maturity-onset diabetes of the young in the pediatric diabetes clinic.
Diagnostic screening of MODY2/GCK mutations in the Norwegian MODY Registry.
Diagnostic screening of NEUROD1 (MODY6) in subjects with MODY or gestational diabetes mellitus.
Differential expression of genes and changes in glucose metabolism in the liver of liver-specific glucokinase gene knockout mice.
Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet.
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
Discovery of a novel phenylethyl benzamide glucokinase activator for the treatment of type 2 diabetes mellitus.
Discovery of a novel site regulating glucokinase activity following characterisation of a new mutation causing hyperinsulinaemic hypoglycaemia in humans.
Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus.
Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemia.
Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation.
Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia.
Discovery of piragliatin-first glucokinase activator studied in type 2 diabetic patients.
Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic ?-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection.
Dose-Dependent Effect of Piragliatin, a Glucokinase Activator, on the QT Interval Following Short-Term Multiple Doses in Patients With Type 2 Diabetes Mellitus.
Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus.
Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin.
Early gene-diet interaction between glucokinase regulatory protein (GCKR) polymorphism, vegetable and fish intakes in modulating triglyceride levels in healthy adolescents.
Early-onset type 2 (non-insulin-dependent) diabetes mellitus is associated with glucokinase locus, but not with adenosine deaminase locus, in the Japanese population.
Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus.
Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes.
Effects of novel maturity-onset diabetes of the young (MODY)-associated mutations on glucokinase activity and protein stability.
Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus.
Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity.
Efficacy and safety of glucokinase activators for type 2 diabetes mellitus therapy: a meta-analysis of double-blind randomized controlled trials.
Essential role of glucokinase in the protection of pancreatic ? cells to the glucose energetic status.
Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.
Evolution- and structure-based computational strategy reveals the impact of deleterious missense mutations on MODY 2 (maturity-onset diabetes of the young, type 2).
Exploring the in vivo mechanisms of action of glucokinase activators in type 2 diabetes.
Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus.
Four Cases of Maturity Onset Diabetes of the Young (MODY) Type 5 Associated with Mutations in the Hepatocyte Nuclear Factor 1 Beta (HNF1B) Gene Presenting in a 13-Year-Old Boy and in Adult Men Aged 33, 34, and 35 Years in Poland.
Four novel mutations, including the first gross deletion in TCF1, identified in HNF-4alpha, GCK and TCF1 in patients with MODY in Israel.
From clinicogenetic studies of maturity-onset diabetes of the young to unraveling complex mechanisms of glucokinase regulation.
Functional glucokinase regulator gene variants have inverse effects on triglyceride and glucose levels, and decrease the risk of obesity in children.
Functional Inactivation of Drosophila GCK Orthologs Causes Genomic Instability and Oxidative Stress in a Fly Model of MODY-2.
G(-30)A polymorphism in the pancreatic promoter of the glucokinase gene associated with angiographic coronary artery disease and type 2 diabetes mellitus.
GCK and HNF1A mutations in Canadian families with maturity onset diabetes of the young (MODY).
GCK monogenic diabetes and gestational diabetes: possible diagnosis on clinical grounds.
GCK Mutation in a Child with Maturity Onset Diabetes of the Young, Type 2.
GCK mutations in Chinese MODY2 patients: a family pedigree report and review of Chinese literature.
Generation of N-ethyl-N-nitrosourea (ENU) diabetes models in mice demonstrates genotype-specific action of glucokinase activators.
Generation of two human iPSC lines from patients with maturity-onset diabetes of the young type 2 (MODY2) and permanent neonatal diabetes due to mutations in the GCK gene.
Genetic analysis of glucokinase and the chromosome 20 diabetes susceptibility locus in families with type 2 diabetes.
Genetic and bioinformatics analysis of four novel GCK missense variants detected in Caucasian families with GCK-MODY phenotype.
Genetic and clinical characteristics of Korean maturity-onset diabetes of the young (MODY) patients.
Genetic and clinical characteristics of maturity-onset diabetes of the young in Chinese patients.
Genetic approaches to common diseases.
Genetic basis of maturity-onset diabetes of the young.
Genetic causes of maturity onset diabetes of the young may be less prevalent in American pregnant women recently diagnosed with diabetes mellitus than in previously studied European populations.
Genetic determinants of type 2 diabetes mellitus: lessons learned from family studies.
Genetic polymorphism of glucokinase on the risk of type 2 diabetes and impaired glucose regulation: evidence based on 298, 468 subjects.
Genetic testing for glucokinase mutations in clinically selected patients with MODY: a worthwhile investment.
Genetic testing for maturity onset diabetes of the young in childhood hyperglycaemia.
Genetic testing of GCK-MODY identifies a novel pathogenic variant in a Chinese boy with early onset hyperglycemia.
Genetic Testing of Maturity-Onset Diabetes of the Young Current Status and Future Perspectives.
Genetic variation in the hepatocyte nuclear factor-3beta gene (HNF3B) does not contribute to maturity-onset diabetes of the young in French Caucasians.
Genetics of non-insulin-dependent (type-II) diabetes mellitus.
Genetics of type 2 diabetes mellitus.
Genomic analysis of five chromosome 7p deletion patients with Greig cephalopolysyndactyly syndrome (GCPS).
Genotype-phenotype Characteristics of Turkish Children with Glucokinase Mutations Associated Maturity-onset Diabetes in the Young.
Glucagon-like peptide-1 enhances glucokinase activity in pancreatic ?-cells through the association of Epac2 with Rim2 and Rab3A.
Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy.
Glucokinase activation or inactivation: Which will lead to the treatment of type 2 diabetes?
Glucokinase activators for the potential treatment of type 2 diabetes.
Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments.
Glucokinase and MODY: from the gene to the disease.
Glucokinase and molecular aspects of liver glycogen metabolism.
Glucokinase and NIDDM. A candidate gene that paid off.
Glucokinase and the potential of glucokinase activation in type 2 diabetes.
Glucokinase diabetes in 103 families from a country-based study in the Czech Republic: geographically restricted distribution of two prevalent GCK mutations.
Glucokinase gene in gestational diabetes mellitus: population association study and molecular scanning.
Glucokinase gene is genetic marker for NIDDM in American blacks.
Glucokinase gene islet promoter region variant (G-->A) at nucleotide -30 is not associated with reduced insulin secretion in Finns.
Glucokinase gene locus transgenic mice are resistant to the development of obesity-induced type 2 diabetes.
Glucokinase gene mutation linked to early-onset NIDDM.
Glucokinase Gene Mutation Screening in Argentinean Clinically Characterized MODY Patients.
Glucokinase gene mutations (MODY 2) in Asian Indians.
Glucokinase gene mutations: structural and genotype-phenotype analyses in MODY children from South Italy.
Glucokinase gene polymorphisms: a genetic marker for glucose intolerance in a cohort of elderly Finnish men.
Glucokinase gene variants in Chinese subjects with the common form of NIDDM.
Glucokinase gene variants in subjects with late-onset NIDDM and impaired glucose tolerance.
Glucokinase gene variants in the common form of NIDDM.
Glucokinase gene variations in Japanese-Americans with a family history of NIDDM.
Glucokinase in stellate ganglia cooperates with P2X3 receptor to develop cardiac sympathetic neuropathy in type 2 diabetes rats.
Glucokinase Inactivation Paradoxically Ameliorates Glucose Intolerance by Increasing Beta-Cell Mass in db/db Mice.
Glucokinase MODY and implications for treatment goals of common forms of diabetes.
Glucokinase mutations associated with non-insulin-dependent (type 2) diabetes mellitus have decreased enzymatic activity: implications for structure/function relationships.
Glucokinase mutations, insulin secretion, and diabetes mellitus.
Glucokinase regulates reproductive function, glucocorticoid secretion, food intake, and hypothalamic gene expression.
Glucosamine inhibits glucokinase in vitro and produces a glucose-specific impairment of in vivo insulin secretion in rats.
Glucose modulation of ATP-sensitive K-currents in wild-type, homozygous and heterozygous glucokinase knock-out mice.
Glucose production, utilization, and cycling in response to moderate exercise in obese subjects with type 2 diabetes and mild hyperglycemia.
Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity.
Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study.
Haploinsufficiency at GCK gene is not a frequent event in MODY2 patients.
Hepatic function in a family with a nonsense mutation (R154X) in the hepatocyte nuclear factor-4alpha/MODY1 gene.
Hepatic glucokinase promoter polymorphism is associated with hepatic insulin resistance in Asian Indians.
Hepatic glycogen cycling contributes to glucose lowering effects of the glucokinase activator LCZ960.
Hepatocyte nuclear factor 1 alpha (HNF-1 alpha) mutations in maturity-onset diabetes of the young.
High frequency of mutations in MODY and mitochondrial genes in Scandinavian patients with familial early-onset diabetes.
High prevalence of a missense mutation of the glucokinase gene in gestational diabetic patients due to a founder-effect in a local population.
High prevalence of glucokinase mutations in Italian children with MODY. Influence on glucose tolerance, first-phase insulin response, insulin sensitivity and BMI. Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetes (SIEDP).
High-resolution electrospray ionization Fourier transform mass spectrometry with infrared multiphoton dissociation of glucokinase from Bacillus Stearothermophilus.
High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes.
Homotropic allosteric regulation in monomeric mammalian glucokinase.
Hormonal and Metabolite Regulation of Hepatic Glucokinase.
Human glucokinase gene: isolation, characterization, and identification of two missense mutations linked to early-onset non-insulin-dependent (type 2) diabetes mellitus.
Human glucokinase gene: isolation, structural characterization, and identification of a microsatellite repeat polymorphism.
Human glucokinase regulatory protein (GCKR): cDNA and genomic cloning, complete primary structure, and chromosomal localization.
Human hexokinase II: localization of the polymorphic gene to chromosome 2.
Hypoglycemic effects of a phenolic acid fraction of rice bran and ferulic acid in C57BL/KsJ-db/db mice.
Identification and analysis of novel R308K mutation in glucokinase of type 2 diabetic patient and its kinetic correlation.
Identification and functional characterisation of novel glucokinase mutations causing maturity-onset diabetes of the young in Slovakia.
Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families.
Identification of 21 novel glucokinase (GCK) mutations in UK and European Caucasians with maturity-onset diabetes of the young (MODY).
Identification of eight novel glucokinase mutations in Italian children with maturity-onset diabetes of the young.
Identification of glucokinase mutation in subjects with post-renal transplantation diabetes mellitus.
Identification of glucokinase mutations in subjects with gestational diabetes mellitus.
Identification of Maturity-Onset Diabetes of the Young Caused by Glucokinase Mutations Detected Using Whole-Exome Sequencing.
Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.
Identification of novel GCK and HNF1A/TCF1 mutations and polymorphisms in German families with maturity-onset diabetes of the young (MODY).
Identification of novel polymorphisms in the glucokinase and glucose-6-phosphatase genes in infants who died suddenly and unexpectedly.
Identification of RO4597014, a Glucokinase Activator Studied in the Clinic for the Treatment of Type 2 Diabetes.
Identification of two new mutations in the glucokinase gene that result in maturity-onset diabetes of the young.
Identification of YH-GKA, a novel benzamide glucokinase activator as therapeutic candidate for type 2 diabetes mellitus.
Impact of Type 2 diabetes on Glucokinase diabetes (GCK-MODY) phenotype in a Roma (Gypsy) family - case report.
Impairment of glucokinase translocation in cultured hepatocytes from OLETF and GK rats, animal models of type 2 diabetes.
Importance of glucokinase -258G/A polymorphism in Asian Indians with post-transplant and type 2 diabetes mellitus.
Improved metabolic stimulus for glucose-induced insulin secretion through GK and PFK-2/FBPase-2 coexpression in insulin-producing RINm5F cells.
Increased potency and efficacy of combined phosphorylase inactivation and glucokinase activation in control of hepatocyte glycogen metabolism.
Incretin Effect and Glucagon Responses to Oral and Intravenous Glucose in Patients with Maturity Onset Diabetes of the Young - Type 2 and Type 3.
Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Insights into the structure and regulation of glucokinase from a novel mutation (V62M), which causes maturity-onset diabetes of the young.
Interaction effect of genetic polymorphisms in glucokinase (GCK) and glucokinase regulatory protein (GCKR) on metabolic traits in healthy Chinese adults and adolescents.
Interindividual variations in metabolism and pharmacokinetics of 3-(6-methylpyridine-3-yl-sulfanyl)-6-(4H-[1,2,4]triazole-3-yl-sulfanyl)-N-(1,3-thiazole-2-yl)-2-pyridine carboxamide, a glucokinase activator, in rats caused by the genetic polymorphism of CYP2D1.
Intima-media thickness and endothelial dysfunction in GCK and HNF1A-MODY patients.
Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes.
iPSC-derived ? cells model diabetes due to glucokinase deficiency.
L-Arginine prevents cereblon-mediated ubiquitination of glucokinase and stimulates glucose-6-phosphate production in pancreatic ?-cells.
Lack of Potential Pharmacokinetic and Pharmacodynamic Interactions Between Piragliatin, a Glucokinase Activator, and Simvastatin in Patients With Type 2 Diabetes Mellitus.
Lessons from glucokinase activators: the problem of declining efficacy.
Lessons from transgenic and knockout animals about noninsulin-dependent diabetes mellitus.
Lilly Lecture 1994. The beta-cell in diabetes: from molecular genetics to clinical research.
Linkage analysis and molecular scanning of glucokinase gene in NIDDM families.
Linkage analysis does not support a role for glucokinase gene in the aetiology of type 2 diabetes mellitus among north western Italians.
Linkage analysis of acute insulin secretion with GLUT2 and glucokinase in Pima Indians and the identification of a missense mutation in GLUT2.
Linkage analysis of glucokinase gene with NIDDM in Caucasian pedigrees.
Linkage analysis of the genetic markers of the candidate genes with non-insulin dependent diabetes mellitus in Chinese families.
Linkage analysis of the glucokinase locus in familial type 2 (non-insulin-dependent) diabetic pedigrees.
Linkage of maturity-onset diabetes of the young to the glucokinase gene--evidence of genetic heterogeneity.
Linkage of type 2 diabetes to the glucokinase gene.
LncRNA NONRATT021972 siRNA normalized the dysfunction of hepatic glucokinase through AKT signaling in T2DM rats.
Long-term follow-up of oral glucose tolerance test-derived glucose tolerance and insulin secretion and insulin sensitivity indexes in subjects with glucokinase mutations (MODY2).
Long-term renal changes in the liver-specific glucokinase knockout mouse: implications for renal disease in maturity-onset diabetes of the young 2.
Low-Frequency Genetic Variant in the Hepatic Glucokinase Gene Is Associated With Type 2 Diabetes and Insulin Resistance in Chinese Population.
Lys169 of human glucokinase is a determinant for glucose phosphorylation: implication for the atomic mechanism of glucokinase catalysis.
Maturity onset diabetes of the young (MODY).
Maturity Onset Diabetes of the Young due to Glucokinase, HNF1-A, HNF1-B, and HNF4-A Mutations in a Cohort of Turkish Children Diagnosed as Type 1 Diabetes Mellitus.
Maturity Onset Diabetes of the Young is Not Necessarily Associated with Autosomal Inheritance: Case Description of a De Novo HFN1A Mutation.
Maturity onset diabetes of the young type 2 (MODY2): Insight from an extended family.
Maturity-onset diabetes of the young (MODY) in Brazil: Establishment of a national registry and appraisal of available genetic and clinical data.
Maturity-onset diabetes of the young (MODY): a new challenge for pediatric diabetologists.
Maturity-onset diabetes of the young (MODY): an update.
Maturity-onset diabetes of the young (MODY): current perspectives on diagnosis and treatment.
Maturity-Onset Diabetes of the Young (MODY): Making the Right Diagnosis to Optimize Treatment.
Maturity-onset diabetes of the young.
Maturity-onset diabetes of the young: clinical heterogeneity explained by genetic heterogeneity.
Maturity-onset diabetes of the young: Different diabetes in an infant with cystic fibrosis.
Maturity-onset diabetes of the young: from clinical description to molecular genetic characterization.
Medicinal Chemistry Approaches for Glucokinase Activation to Treat Type 2 Diabetes.
Metabolic diseases drug discovery world summit. July 28-29, 2003, San Diego, CA, USA.
Metabolic Profiling in Maturity-Onset Diabetes of the Young (MODY) and Young Onset Type 2 Diabetes Fails to Detect Robust Urinary Biomarkers.
Metabolite profiling reveals normal metabolic control in carriers of mutations in the glucokinase gene (MODY2).
Microsatellite polymorphisms at the glucokinase locus: a population association study in Caucasian type 2 diabetic subjects.
Mild fasting hyperglycemia in children: high rate of glucokinase mutations and some risk of developing type 1 diabetes mellitus.
Minigene splicing assessment of 20 novel synonymous and intronic glucokinase gene variants identified in patients with maturity onset diabetes of the young.
Missense glucokinase mutation in maturity-onset diabetes of the young and mutation screening in late-onset diabetes.
Mitochondria and diabetes. Genetic, biochemical, and clinical implications of the cellular energy circuit.
Mitochondrial diabetes: molecular mechanisms and clinical presentation.
Modulation of Glucokinase Regulatory Protein: A Double-Edged Sword?
MODY 2: mutation identification and molecular ancestry in a Brazilian family.
MODY diabetes and screening of gestational diabetes.
MODY Type 2 P59S GCK mutant: founder effect in South of Italy.
MODY2 caused by a novel mutation of GCK gene.
Molecular and biochemical analysis of the MODY syndromes.
Molecular and clinical characterization of glucokinase maturity-onset diabetes of the young (GCK-MODY) in Japanese patients.
Molecular changes in the Glucokinase gene (GCK) associated with the diagnosis of Maturity Onset Diabetes of the Young (MODY) in pregnant women and newborns.
Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict Protein-Ligand Residence Times.
Molecular genetics goes to the diabetes clinic.
Molecular genetics of diabetes mellitus in Chinese subjects: identification of mutations in glucokinase and hepatocyte nuclear factor-1alpha genes in patients with early-onset type 2 diabetes mellitus/MODY.
Molecular Genetics of Maturity-onset Diabetes of the Young.
Molecular model of human beta-cell glucokinase built by analogy to the crystal structure of yeast hexokinase B.
Molecular screening of the glucokinase gene in familial type 2 (non-insulin-dependent) diabetes mellitus.
Molecular targeting of pancreatic disorders.
Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes.
Monogenic disorders of the pancreatic ?-cell: personalizing treatment for rare forms of diabetes and hypoglycemia.
Monogenic forms of obesity and diabetes mellitus.
Monogenic glucokinase diabetes and pregnancy: a case study.
Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis.
Mutation screening in 18 Caucasian families suggest the existence of other MODY genes.
Mutations in exons 10 and 11 of human Glucokinase results in conformational variations in the active site of the structure contributing to poor substrate binding - explains hyperglycemia in type 2 diabetic patients.
Mutations in HNF1A Result in Marked Alterations of Plasma Glycan Profile.
Mutations in MODY genes are not common cause of early-onset type 2 diabetes in Mexican families.
Mutations in pancreatic ß-cell Glucokinase as a cause of hyperinsulinaemic hypoglycaemia and neonatal diabetes mellitus.
Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young.
Mutations in the glucokinase gene are not a major cause of late-onset type 2 (non-insulin-dependent) diabetes mellitus in Japanese subjects.
Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1)
Mutations of the glucokinase gene and type 2 diabetes.
NAPDH oxidase mediates glucolipotoxicity-induced beta cell dysfunction - Clinical implications.
NIDDM--genetic marker; glucose transporter, glucokinase, and mitochondria gene.
Nine novel mutations in maturity-onset diabetes of the young (MODY) candidate genes in 22 Spanish families.
Non-insulin dependent diabetes--the past, present and future.
Nonradioactive screening of glucokinase mutations in maturity onset diabetes of the young.
Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus.
Nonsense mutation of glucokinase gene in late-onset non-insulin-dependent diabetes mellitus.
Novel glucokinase activators: a patent review (2008 - 2010).
Novel glucokinase gene mutation in the first Macedonian family tested for MODY.
Novel polymorphisms in the GCKR gene and their influence on glucose and insulin levels in a Danish twin population.
Novel susceptibility gene for late-onset NIDDM is localized to human chromosome 12q.
Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.
Nuclear magnetic resonance studies of hepatic glucose metabolism in humans.
Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes.
Organization of the human glucokinase regulator gene GCKR.
Pancreatic pathology in non-insulin dependent diabetes (NIDDM).
Parent-offspring trios: a resource to facilitate the identification of type 2 diabetes genes.
Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young.
Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy.
Pathogenicity of a glucokinase gene mutation and description of its clinical phenotype.
Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Piragliatin, a Glucokinase Activator, and Glyburide, a Sulfonylurea, in Type 2 Diabetic Patients.
Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
Phenotypic and pathomorphological characteristics of a novel mutant mouse model for maturity-onset diabetes of the young type 2 (MODY 2).
Physiology and pathology of islet metabolism.
Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study.
Polymorphic microsatellite repeat markers at the glucokinase gene locus are positively associated with NIDDM in Japanese.
Polymorphism of glucokinase gene in non-insulin dependent diabetes mellitus.
Polymorphisms in genes involved in glucose metabolism in cases of sudden infant death syndrome.
Polymorphisms rs144723656, rs2268574, and rs2268575 of the glucokinase gene are not associated with obese women with type 2 diabetes mellitus.
Positive association in the absence of linkage suggests a minor role for the glucokinase gene in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus amongst south Indians.
Precision Therapy for a Chinese Family With Maturity-Onset Diabetes of the Young.
Preliminary screening of mutations in the glucokinase gene of Chinese patients with gestational diabetes.
Present status of clinical deployment of glucokinase activators.
Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia.
Prevalence, Characteristics and Clinical Diagnosis of Maturity Onset Diabetes of the Young Due to Mutations in HNF1A, HNF4A, and Glucokinase: Results From the SEARCH for Diabetes in Youth.
Primary pancreatic beta-cell secretory defect caused by mutations in glucokinase gene in kindreds of maturity onset diabetes of the young.
Promoter variation in the liver glucokinase is a risk factor for non-insulin-dependent diabetes mellitus.
Property-based design in the optimisation of benzamide glucokinase activators: from hit to clinic.
Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus.
Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif.
Recent advances in glucokinase activators for the treatment of type 2 diabetes.
Recent clinical advances of glucokinase activators in the treatment of diabetes mellitus type 2.
Recent Developments in Medicinal Chemistry of Allosteric Activators of Human Glucokinase for Type 2 Diabetes Mellitus Therapeutics.
Recent Updates on Glucokinase Activators and Glucokinase Regulatory Protein Disrupters for the Treatment of Type 2 Diabetes Mellitus.
Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus.
Repair of diverse diabetic defects of ?-cells in man and mouse by pharmacological glucokinase activation.
Role of glucose-6 phosphatase, glucokinase, and glucose-6 phosphate in liver insulin resistance and its correction by metformin.
Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.
Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study.
Screening of mutations and polymorphisms in the glucokinase gene in Czech diabetic and healthy control populations.
Screening of mutations in the GCK gene in Jordanian maturity-onset diabetes of the young type 2 (MODY2) patients.
Search for a third susceptibility gene for maturity-onset diabetes of the young. Studies with eleven candidate genes.
Searching for genes in diabetes and the metabolic syndrome.
Searching for Maturity-Onset Diabetes of the Young (MODY): When and What for?
Sequence variations of the glucokinase gene in Japanese subjects with NIDDM.
Single-strand conformation polymorphism analysis of the glucose transporter gene GLUT1 in maturity-onset diabetes of the young.
Six mutations in the glucokinase gene identified in MODY by using a nonradioactive sensitive screening technique.
Small molecular glucokinase activators: Has another new anti-diabetic therapeutic lost favour.
Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy.
Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans.
Specific insulin and proinsulin secretion in glucokinase-deficient individuals.
Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators.
Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes.
Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase.
Structural instability of mutant beta-cell glucokinase: implications for the molecular pathogenesis of maturity-onset diabetes of the young (type-2).
Structure based design, synthesis and biological evaluation of amino phosphonate derivatives as human glucokinase activators.
Structure of the human glucokinase gene and identification of a missense mutation in a Japanese patient with early-onset non-insulin-dependent diabetes mellitus.
Targeting hepatic glucokinase in type 2 diabetes: weighing the benefits and risks.
Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator.
The 0.1% of the Population With Glucokinase Monogenic Diabetes Can be Recognized by Clinical Characteristics in Pregnancy: The Atlantic Diabetes in Pregnancy Cohort.
The APOE?3-Leiden Heterozygous Glucokinase Knockout Mouse as Novel Translational Disease Model for Type 2 Diabetes, Dyslipidemia, and Diabetic Atherosclerosis.
The beta cell in NIDDM: giving light to the blind.
The clinical management of hyperglycemia in pregnancy complicated by maturity-onset diabetes of the young.
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus.
The effects and safety of activators of glucokinase versus placebo in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
The genetic abnormality in the beta cell determines the response to an oral glucose load.
The genetic basis of diabetes mellitus.
The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food.
The glucokinase mutation p.T206P is common among MODY patients of Jewish Ashkenazi descent.
The human glucokinase gene beta-cell-type promoter: an essential role of insulin promoter factor 1/PDX-1 in its activation in HIT-T15 cells.
The influence of dietary carbohydrate content on glycaemia in patients with glucokinase maturity-onset diabetes of the young.
The pancreatic beta-cell glucose sensor.
The potential role of glucokinase activator SHP289-04 in anti-diabetes and hepatic protection.
The prevalence of monogenic diabetes in Australia: the Fremantle Diabetes Study Phase II.
The Relationship of Glucokinase Activator-induced Hypoglycemia with Arteriopathy, Neuronal Necrosis, and Peripheral Neuropathy in Nonclinical Studies.
The role of the regulatory protein of glucokinase in the glucose sensory mechanism of the hepatocyte.
Therapy targeting beta-cell survival and function in type 2 diabetes mellitus.
Three novel missense mutations in the glucokinase gene (G80S; E221K; G227C) in Italian subjects with maturity-onset diabetes of the young (MODY). Mutations in brief no. 162. Online.
Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp.
Treatment of type 2 diabetes by adenoviral-mediated overexpression of the glucokinase regulatory protein.
TTP399: an investigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetes.
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
Two microsatellite repeat polymorphisms flanking opposite ends of the human glucokinase gene: use in haplotype analysis of Welsh Caucasians with type 2 (non-insulin-dependent) diabetes mellitus.
Type 2 (non-insulin-dependent) diabetes mellitus associated with a mutation of the glucokinase gene in a Japanese family.
Type 2 diabetes impairs splanchnic uptake of glucose but does not alter intestinal glucose absorption during enteral glucose feeding: additional evidence for a defect in hepatic glucokinase activity.
Type II diabetes: search for primary defects.
Update on clinical screening of maturity-onset diabetes of the young (MODY).
Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia.
Utilization of the Zucker Diabetic Fatty (ZDF) Rat Model for Investigating Hypoglycemia-related Toxicities.
Variable effects of maturity-onset-diabetes-of-youth (MODY)-associated glucokinase mutations on substrate interactions and stability of the enzyme.
Variant forms of glucokinase gene in Japanese patients with late-onset type 2 diabetes.
[A novel mutation W257R in GCK gene discovered from a Chinese patient with maturity onset diabetes of the young].
[A rare cause of diabetes mellitus].
[A three-year follow-up observation of a pedigree of maturity onset diabetes of the young caused by a novel mutation of glucokinase and literature review].
[Association of GCKR gene polymorphisms and type 2 diabetes among ethnic Uygurs].
[Current treatment options in Maturity-Onset Diabetes of the Young].
[Diabetes mellitus caused by a mutation of glucokinase gene. Report of an affected family].
[Diagnosis of MODY - brief overview for clinical practice].
[Effects of berberine on expression of hepatocyte nuclear factor 4alpha and glucokinase activity in mouse primary hepatocytes]
[Genetic diagnosis of diabetes mellitus]
[Genetics of type 2 diabetes mellitus: genes implicated in early onset diabetes]
[Genetics of type II diabetes]
[Glucokinase gene abnormalities in maturity-onset diabetes of the young (MODY) and late-onset NIDDM]
[Glucokinase gene mutation as a causative factor of permanent neonatal diabetes mellitus].
[Glucokinase gene mutations in gestational diabetes in Polish population. Prediction of diabetes mellitus development after delivery]
[Heterogeneity in pathogenesis of NIDDM and recent advances in research of diabetogenic genes]
[Maturity onset diabetes of the young (MODY)-screening, diagnostic and therapy].
[Maturity onset diabetes of the young: just think about it].
[Maturity-onset diabetes of the young--MODY. Molecular-genetic, pathophysiological and clinical characteristics]
[MODY type diabetes: an often-misunderstood entity].
[MODY types of diabetes mellitus]
[MODY, a model of genotype/phenotype interactions in type 2 diabetes]
[Monogenic forms of diabetes mellitus]
[Mutation of GCK gene of Chinese patients with late-onset type 2 diabetes]
[Mutations of glucokinase gene in Japanese subjects with NIDDM]
[New aspects of pancreatic beta cell functions and their possible therapeutic applications]
[NIDDM susceptibility genes]
[Novel glucokinase mutation in a boy with maturity-onset diabetes of the young]
[Pathogenesis of impaired insulin secretion in NIDDM]
[The functional analysis of glucokinase gene E339K mutation].
Diabetes, Gestational
A case-control study and meta-analysis confirm glucokinase regulatory gene rs780094 is a risk factor for gestational diabetes mellitus.
A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria.
Association of the glucokinase gene promoter polymorphism -30G > A (rs1799884) with gestational diabetes mellitus susceptibility: a case-control study and meta-analysis.
Comment on Rudland et al. Identifying Glucokinase Monogenic Diabetes in a Multiethnic Gestational Diabetes Mellitus Cohort: New Pregnancy Screening Criteria and Utility of HbA1c. Diabetes Care 2016;39:50-52.
Diagnostic screening of NEUROD1 (MODY6) in subjects with MODY or gestational diabetes mellitus.
GCK monogenic diabetes and gestational diabetes: possible diagnosis on clinical grounds.
Genetic causes of maturity onset diabetes of the young may be less prevalent in American pregnant women recently diagnosed with diabetes mellitus than in previously studied European populations.
Gestational diabetes mellitus and gene mutations which affect insulin secretion.
Glucokinase gene in gestational diabetes mellitus: population association study and molecular scanning.
Glucokinase mutations in a phenotypically selected multiethnic group of women with a history of gestational diabetes.
High prevalence of a missense mutation of the glucokinase gene in gestational diabetic patients due to a founder-effect in a local population.
Homozygosity for a common polymorphism in the islet-specific promoter of the glucokinase gene is associated with a reduced early insulin response to oral glucose in pregnant women.
Identification of glucokinase mutations in subjects with gestational diabetes mellitus.
Identifying Glucokinase Monogenic Diabetes in a Multiethnic Gestational Diabetes Mellitus Cohort: New Pregnancy Screening Criteria and Utility of HbA1c.
Influence of maternal and fetal glucokinase mutations in gestational diabetes.
Linkage analysis and molecular scanning of glucokinase gene in NIDDM families.
MiR-330-3p contributes to INS-1 cell dysfunction by targeting glucokinase in gestational diabetes mellitus.
Monogenic diabetes caused by GCK gene mutation is misdiagnosed as gestational diabetes - A multicenter study in Portugal.
Monogenic glucokinase diabetes and pregnancy: a case study.
Preliminary screening of mutations in the glucokinase gene of Chinese patients with gestational diabetes.
The 0.1% of the Population With Glucokinase Monogenic Diabetes Can be Recognized by Clinical Characteristics in Pregnancy: The Atlantic Diabetes in Pregnancy Cohort.
The association of the glucokinase rs4607517 polymorphism with gestational diabetes mellitus and its interaction with sweets consumption in Chinese women.
The glucokinase gene promoter polymorphism -30G>A (rs1799884) is associated with fasting glucose in healthy pregnant women but not with gestational diabetes.
The glucokinase mutation p.T206P is common among MODY patients of Jewish Ashkenazi descent.
The polymorphism rs2268574 in Glucokinase gene is associated with gestational Diabetes mellitus.
Three novel missense mutations in the glucokinase gene (G80S; E221K; G227C) in Italian subjects with maturity-onset diabetes of the young (MODY). Mutations in brief no. 162. Online.
[Association of glucokinase gene with gestational diabetes mellitus in Chinese]
[Glucokinase gene mutations in gestational diabetes in Polish population. Prediction of diabetes mellitus development after delivery]
Diabetic Cardiomyopathies
Long term liver specific glucokinase gene defect induced diabetic cardiomyopathy by up regulating NADPH oxidase and down regulating insulin receptor and p-AMPK.
Diabetic Neuropathies
NONRATT021972 long-noncoding RNA: A promising lncRNA in diabetes-related diseases.
Dyslipidemias
A Common Gene Variant in Glucokinase Regulatory Protein Interacts With Glucose Metabolism on Diabetic Dyslipidemia: the Combined CODAM and Hoorn Studies.
Associations of apolipoprotein A5 (APOA5), glucokinase (GCK) and glucokinase regulatory protein (GCKR) polymorphisms and lifestyle factors with the risk of dyslipidemia and dysglycemia in Japanese - a cross-sectional data from the J-MICC Study.
Associations of common polymorphisms in GCKR with type 2 diabetes and related traits in a Han Chinese population: a case-control study.
The APOE?3-Leiden Heterozygous Glucokinase Knockout Mouse as Novel Translational Disease Model for Type 2 Diabetes, Dyslipidemia, and Diabetic Atherosclerosis.
Fatty Liver
A glucokinase-like enzyme induced in Mule duck livers by overfeeding.
Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene.
Association of rs780094 polymorphism of glucokinase regulatory protein with non-alcoholic fatty liver disease.
Collagen Formation Assessed by N-Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography.
Correction: glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic Fatty liver disease.
Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic Fatty liver disease.
Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans.
Non-alcoholic fatty liver disease concerns with glucokinase activators - Authors' reply.
Non-alcoholic fatty liver disease concerns with glucokinase activators.
Pediatric non-alcoholic fatty liver disease: New insights and future directions.
Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans.
Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator.
Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents.
Fetal Growth Retardation
Monogenic glucokinase diabetes and pregnancy: a case study.
Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway.
The effect of intrauterine growth restriction upon fetal and postnatal hepatic glucose transporter and glucokinase proteins.
Genetic Diseases, Inborn
Biphasic dynamics of beta cell mass in a mouse model of congenital hyperinsulinism: implications for type 2 diabetes.
Localized increases in CEPT1 and ATGL elevate plasmalogen phosphatidylcholines in HDLs contributing to atheroprotective lipid profiles in hyperglycemic GCK-MODY.
Therapy targeting beta-cell survival and function in type 2 diabetes mellitus.
glucokinase deficiency
ATP-sensitive K+ channel signaling in glucokinase-deficient diabetes.
beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes.
Characterization of the gene expression profile of heterozygous liver-specific glucokinase knockout mice at a young age.
Clinical characteristics of mutation carriers in a large family with glucokinase diabetes (MODY2).
Complete glucokinase deficiency is not a common cause of permanent neonatal diabetes.
Evolution of hepatic glucose metabolism: liver-specific glucokinase deficiency explained by parallel loss of the gene for glucokinase regulatory protein (GCKR).
Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes.
Glucokinase deficiency results in a beta-cell disorder characterised by normal fasting plasma proinsulin concentrations.
Glucose potentiation of arginine-induced insulin secretion is impaired in subjects with a glucokinase Glu256Lys mutation.
Hyperglycemia Induced by Glucokinase Deficiency Accelerates Atherosclerosis Development and Impairs Lesion Regression in Combined Heterozygous Glucokinase and the Apolipoprotein E-Knockout Mice.
Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families.
iPSC-derived ? cells model diabetes due to glucokinase deficiency.
Management of neonatal and infancy-onset diabetes mellitus.
Monogenic glucokinase diabetes and pregnancy: a case study.
Neonatal diabetes mellitus due to complete glucokinase deficiency.
Neonatal Diabetes Mellitus: Novel Mutations.
New perspectives on pancreatic islet glucokinase.
Permanent neonatal diabetes caused by a homozygous nonsense mutation in the glucokinase gene.
Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway.
Six mutations in the glucokinase gene identified in MODY by using a nonradioactive sensitive screening technique.
[Non-insulin dependent diabetes in children and adolescents]
Glucose Intolerance
A variation at position -30 of the beta-cell glucokinase gene promoter is associated with reduced beta-cell function in middle-aged Japanese-American men.
Acute glucose intolerance in insulinoma cells with unbalanced overexpression of glucokinase.
Alterations in key carbohydrate-metabolizing enzyme activities in rat livers following bile duct ligation and its release.
Chronic ethanol consumption inhibits glucokinase transcriptional activity by Atf3 and triggers metabolic syndrome in vivo.
Control of liver glucokinase activity: A potential new target for incretin hormones?
Deletion of the donor splice site of intron 4 in the glucokinase gene causes maturity-onset diabetes of the young.
Development of non-insulin-dependent diabetes mellitus in the double knockout mice with disruption of insulin receptor substrate-1 and beta cell glucokinase genes. Genetic reconstitution of diabetes as a polygenic disease.
Disruption of hepatic C/EBPalpha results in impaired glucose tolerance and age-dependent hepatosteatosis.
F0 maternal BPA exposure induced glucose intolerance of F2 generation through DNA methylation change in Gck.
Fetal programming of perivenous glucose uptake reveals a regulatory mechanism governing hepatic glucose output during refeeding.
Glucokinase activation or inactivation: Which will lead to the treatment of type 2 diabetes?
Glucokinase gene expression is nutritionally regulated in liver of gilthead sea bream (Sparus aurata).
Glucokinase gene islet promoter region variant (G-->A) at nucleotide -30 is not associated with reduced insulin secretion in Finns.
Glucokinase gene polymorphisms: a genetic marker for glucose intolerance in a cohort of elderly Finnish men.
Glucokinase gene variants in subjects with late-onset NIDDM and impaired glucose tolerance.
Glucokinase gene variants in the common form of NIDDM.
Glucokinase Inactivation Paradoxically Ameliorates Glucose Intolerance by Increasing Beta-Cell Mass in db/db Mice.
Hexokinase isoenzymes in normal and cirrhotic human liver: suppression of glucokinase in cirrhosis.
Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families.
Interleukin-1 reduces the glycolytic utilization of glucose by pancreatic islets and reduces glucokinase mRNA content and protein synthesis by a nitric oxide-dependent mechanism.
Molecular etiologies of MODY and other early-onset forms of diabetes.
More severe impairment of oral than intravenous glucose tolerance in rats after eating a high fat diet.
NIDDM--genetic marker; glucose transporter, glucokinase, and mitochondria gene.
Pioglitazone versus metformin in two rat models of glucose intolerance and diabetes.
Positive association in the absence of linkage suggests a minor role for the glucokinase gene in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus amongst south Indians.
Production of a mouse strain with impaired glucose tolerance by systemic heterozygous knockout of the glucokinase gene and its feasibility as a prediabetes model.
Role of pregnane X receptor in obesity and glucose homeostasis in male mice.
Roles of hepatic glucokinase in intertissue metabolic communication: Examination of novel liver-specific glucokinase knockout mice.
Three novel missense mutations in the glucokinase gene (G80S; E221K; G227C) in Italian subjects with maturity-onset diabetes of the young (MODY). Mutations in brief no. 162. Online.
[Insulin-dependent neonatal and infant diabetes: genetics and physiopathology]
glycerol-3-phosphate dehydrogenase deficiency
The beta cell in NIDDM: giving light to the blind.
Glycogen Storage Disease
Pathophysiology of impaired pulsatile insulin release.
Glycosuria
Improved metabolic disorders of insulin receptor-deficient mice by transgenic overexpression of glucokinase in the liver.
Neonatal islet cell transplantation in the diabetic rat: effect on hepatic enzyme activity and glucose homeostasis.
Gout
Association between gout and polymorphisms in GCKR in male Han Chinese.
Hypercholesterolemia
Alterations in carbohydrate and lipid metabolism induced by a diet rich in coconut oil and cholesterol in a rat model.
Hyperglycemia
A -30G>A polymorphism of the beta-cell-specific glucokinase promoter associates with hyperglycemia in the general population of whites.
A glucokinase-like enzyme carries out glucose phosphorylation in capillaries of normal and spontaneously hyperglycemic rabbits.
A series of maturity onset diabetes of the young, type 2 (MODY2) mouse models generated by a large-scale ENU mutagenesis program.
Abnormal regulation of hepatic glucose output in maturity-onset diabetes of the young caused by a specific mutation of the glucokinase gene.
Abnormal regulation of HGP by hyperglycemia in mice with a disrupted glucokinase allele.
Adaptation to hyperglycemia enhances insulin secretion in glucokinase mutant mice.
Antenatal Diagnosis of Fetal Genotype Determines if Maternal Hyperglycemia Due to a Glucokinase Mutation Requires Treatment.
Autoregulation by glucose of hepatic glucose balance: permissive effect of insulin.
Berberine alleviates hyperglycemia by targeting hepatic glucokinase in diabetic db/db mice.
beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes.
Biochemical Characterization of MODY2 Glucokinase Variants V62M and G72R Reveals Reduced Enzymatic Activities Relative to Wild-type.
Cardiovascular risk assessment by coronary artery calcium score in subjects with maturity-onset diabetes of the young caused by glucokinase mutations.
Characterization of Glucokinase Catalysis from a Pseudo-Dimeric View.
Chronic Mild Hyperglycemia in GCK-MODY Patients Does Not Increase Carotid Intima-Media Thickness.
Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes.
Comment on: Chakera et al. Antenatal diagnosis of fetal genotype determines if maternal hyperglycemia due to a glucokinase mutation requires treatment. Diabetes Care 2012;35:1832-1834.
Correction of diabetic alterations by glucokinase.
Critical reduction in beta-cell mass results in two distinct outcomes over time. Adaptation with impaired glucose tolerance or decompensated diabetes.
Dexamethasone increases glucose cycling, but not glucose production, in healthy subjects.
Differential Effect of LPS on Glucose, Lactate and Inflammatory Markers in the Lungs of Normal and Diabetic Mice.
Differential expression of genes and changes in glucose metabolism in the liver of liver-specific glucokinase gene knockout mice.
Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemia.
Energy-dependent intracellular translocation of glucokinase in rat pancreatic islets.
Exendin-4 activates glucokinase.
Expression of glucokinase in skeletal muscle: a new approach to counteract diabetic hyperglycemia.
Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus.
GCK Mutation in a Child with Maturity Onset Diabetes of the Young, Type 2.
GCK-MODY diabetes as a protein misfolding disease: The mutation R275C promotes protein misfolding, self-association and cellular degradation.
GCK-MODY diabetes associated with protein misfolding, cellular self-association and degradation.
Genetic deletion of a short fragment of glucokinase in rabbit by CRISPR/Cas9 leading to hyperglycemia and other typical features seen in MODY-2.
Genetic regulation of birth weight and fasting glucose by a common polymorphism in the islet cell promoter of the glucokinase gene.
Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy.
Glucokinase deficit and birthweight: does maternal hyperglycemia always meet fetal needs?
Glucokinase expression is regulated by glucose through O-GlcNAc glycosylation.
Glucokinase gene transfer to skeletal muscle of diabetic Zucker fatty rats improves insulin-sensitive glucose uptake.
Glucokinase mutations in young children with hyperglycemia.
Glucose 6-phosphate regulates hepatic glycogenolysis through inactivation of phosphorylase.
Glucose production, utilization, and cycling in response to moderate exercise in obese subjects with type 2 diabetes and mild hyperglycemia.
Glucose-regulated glucose uptake by transplanted muscle cells expressing glucokinase counteracts diabetic hyperglycemia.
Hepatic expression of a targeting subunit of protein phosphatase-1 in streptozotocin-diabetic rats reverses hyperglycemia and hyperphagia despite depressed glucokinase expression.
Hepatic glucose uptake and disposition during short-term high-fat vs. high-fructose feeding.
Hormonal and Metabolite Regulation of Hepatic Glucokinase.
Hyperglycemia Induced by Glucokinase Deficiency Accelerates Atherosclerosis Development and Impairs Lesion Regression in Combined Heterozygous Glucokinase and the Apolipoprotein E-Knockout Mice.
Hypoglycemic and antioxidative effects of hydroxyethyl methylcellulose in mice fed with high fat diet.
Impact of Type 2 diabetes on Glucokinase diabetes (GCK-MODY) phenotype in a Roma (Gypsy) family - case report.
In situ glucose uptake and glucokinase activity of pancreatic islets in diabetic and obese rodents.
Influence of maternal and fetal glucokinase mutations in gestational diabetes.
Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations.
Lilly Lecture 1994. The beta-cell in diabetes: from molecular genetics to clinical research.
Long term liver specific glucokinase gene defect induced diabetic cardiomyopathy by up regulating NADPH oxidase and down regulating insulin receptor and p-AMPK.
Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs.
Long-term follow-up of oral glucose tolerance test-derived glucose tolerance and insulin secretion and insulin sensitivity indexes in subjects with glucokinase mutations (MODY2).
Low glucokinase activity and high rates of gluconeogenesis contribute to hyperglycemia in barn owls (Tyto alba) after a glucose challenge.
Maturity-onset diabetes of the young.
Mechanism by which hyperglycemia inhibits hepatic glucose production in conscious rats. Implications for the pathophysiology of fasting hyperglycemia in diabetes.
Metabolism and fatty acid profile in fat and lean rainbow trout lines fed with vegetable oil: effect of carbohydrates.
Mild fasting hyperglycemia in children: high rate of glucokinase mutations and some risk of developing type 1 diabetes mellitus.
Minireview: pharmacogenetics and beyond: the interaction of therapeutic response, beta-cell physiology, and genetics in diabetes.
MODY2 caused by a novel mutation of GCK gene.
Molecular changes in the Glucokinase gene (GCK) associated with the diagnosis of Maturity Onset Diabetes of the Young (MODY) in pregnant women and newborns.
Monogenic glucokinase diabetes and pregnancy: a case study.
Mutations in exons 10 and 11 of human Glucokinase results in conformational variations in the active site of the structure contributing to poor substrate binding - explains hyperglycemia in type 2 diabetic patients.
Noninvasive Fetal Genotyping by Droplet Digital PCR to Identify Maternally Inherited Monogenic Diabetes Variants.
Normal Glucose Metabolism in Carnivores Overlaps with Diabetes Pathology in Non-Carnivores.
P2Y12 shRNA normalizes inflammatory dysfunctional hepatic glucokinase activity in type 2 diabetic rats.
Peripheral Mechanisms Mediating the Sustained Antidiabetic Action of FGF1 in the Brain.
Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway.
Portal vein glucose entry triggers a coordinated cellular response that potentiates hepatic glucose uptake and storage in normal but not high-fat/high-fructose-fed dogs.
Pre-germinated brown rice extract ameliorates high-fat diet-induced metabolic syndrome.
Precision medicine in diabetes: A non-invasive prenatal diagnostic test for the determination of fetal glucokinase mutations.
Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia.
Rabbit lens and retina phosphorylate glucose through a glucokinase-like enzyme: study in normal and spontaneously hyperglycemic animals.
Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation.
Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus.
Regulatory effects of glucose on the catalytic activity and cellular content of glucokinase in the pancreatic beta cell. Study using cultured rat islets.
Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects.
Response to Comment on: Chakera et al. Antenatal diagnosis of fetal genotype determines if maternal hyperglycemia due to a glucokinase mutation requires treatment. Diabetes Care 2012;35:1832-1834.
Restoration of glucokinase expression in the liver normalizes postprandial glucose disposal in mice with hepatic deficiency of PDK1.
Restoration of hepatic glucokinase expression corrects hepatic glucose flux and normalizes plasma glucose in zucker diabetic fatty rats.
Reversal of type 1 diabetes by engineering a glucose sensor in skeletal muscle.
Should the Clinical Criteria for Suspecting Glucokinase Mutation-Related Hyperglycemia (MODY-2) Be Revisited During Pregnancy?
Six mutations in the glucokinase gene identified in MODY by using a nonradioactive sensitive screening technique.
Structural model of human glucokinase in complex with glucose and ATP: implications for the mutants that cause hypo- and hyperglycemia.
The clinical management of hyperglycemia in pregnancy complicated by maturity-onset diabetes of the young.
The glucokinase mutation p.T206P is common among MODY patients of Jewish Ashkenazi descent.
The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats.
The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy.
The role of hepatic, renal and intestinal gluconeogenic enzymes in glucose homeostasis of juvenile rainbow trout.
TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models.
Translocation of glucokinase in pancreatic beta-cells during acute and chronic hyperglycemia.
Treatment of Diabetes and Long-term Survival Following Insulin and Glucokinase Gene Therapy.
Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia.
Weaning stage hyperglycemia induces glucose-insensitivity in arcuate POMC neurons and hyperphagia in type 2 diabetic GK rats.
Who should have genetic testing for MODY?
Zhenqing recipe improves glucose metabolism and insulin sensitivity by repressing hepatic FOXO1 in type 2 diabetic rats.
Hyperinsulinism
A glucokinase gene mutation in a young boy with diabetes mellitus, hyperinsulinemia, and insulin resistance.
beta-cell stimulus - secretion coupling defects in rodent models of obesity.
Biphasic dynamics of beta cell mass in a mouse model of congenital hyperinsulinism: implications for type 2 diabetes.
Control of liver glucokinase activity: A potential new target for incretin hormones?
Derangement in hepatic enzymes caused by sucrose-drinking and its implication for the development of hyperglycemia in female Wistar fatty rats.
Diagnostic difficulties in glucokinase hyperinsulinism.
Differential regulation of glucokinase activity in pancreatic islets and liver of the rat.
Dominantly inherited hyperinsulinaemic hypoglycaemia.
Effects of the ethanol extract of the roots of Brassica rapa on glucose and lipid metabolism in C57BL/KsJ-db/db mice.
Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism due to glucokinase activating mutations.
Familial adult onset hyperinsulinism due to an activating glucokinase mutation: implications for pharmacological glucokinase activation.
Family with autosomal dominant hyperinsulinism associated with A456V mutation in the glucokinase gene.
Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy.
Glucokinase gene transfer to skeletal muscle of diabetic Zucker fatty rats improves insulin-sensitive glucose uptake.
Hepatic glucose uptake and disposition during short-term high-fat vs. high-fructose feeding.
Hepatic insulin resistance induced by chronic hindlimb ischemia.
Heterogeneity in phenotype of hyperinsulinism caused by activating glucokinase mutations: a novel mutation and its functional characterization.
Homotropic allosteric regulation in monomeric mammalian glucokinase.
Impact of insulin and glucocorticoid signalling on hepatic glucose homeostasis in the rat exposed to high-fructose diet and chronic stress.
In vivo effects of hyperinsulinemia on lipogenic enzymes and glucose transporter expression in rat liver and adipose tissues.
Mechanism of compensatory hyperinsulinemia in normoglycemic insulin-resistant spontaneously hypertensive rats. Augmented enzymatic activity of glucokinase in beta-cells.
Monogenic hyperinsulinemic hypoglycemia: current insights into the pathogenesis and management.
Portal vein glucose entry triggers a coordinated cellular response that potentiates hepatic glucose uptake and storage in normal but not high-fat/high-fructose-fed dogs.
Restoration of glucokinase expression in the liver normalizes postprandial glucose disposal in mice with hepatic deficiency of PDK1.
Short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with hyperinsulinism: a novel glucose-fatty acid cycle?
The effects of pregnancy steroids on adaptation of beta cells to pregnancy involve the pancreatic glucose sensor glucokinase.
The genetics of neonatal hyperinsulinism.
Hyperlipidemias
Hyperlipemia in the gerbil: effect of diet on serum lipids and hepatic glucokinase.
Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia.
Hypersensitivity
Cell specific differences in DNase I hypersensitivity between the two promoters of the rat glucokinase gene.
Changes induced by sucrose administration on glucose metabolism in pancreatic islets in normal hamsters.
Induction of the glucokinase gene by insulin in cultured neonatal rat hepatocytes. Relationship with DNase-I hypersensitive sites and functional analysis of a putative insulin-response element.
Hypertension
G/A Polymorphism at -258 of the Hepatic Glucokinase Promoter Is Not Associated with Decreased Birth Weight in Preterm Neonates.
Hyperthyroidism
Effect of different thyroid states on rat liver glucokinase synthesis and degradation in vivo.
Response of hepatic glucokinase and glucose-6-phosphatase activities in juvenile and adult hyperthyroid mice.
Hypertriglyceridemia
A Common Gene Variant in Glucokinase Regulatory Protein Interacts With Glucose Metabolism on Diabetic Dyslipidemia: the Combined CODAM and Hoorn Studies.
Control of liver glucokinase activity: A potential new target for incretin hormones?
Impaired beta-cell function and deposition of fat droplets in the pancreas as a consequence of hypertriglyceridemia in OLETF rat, a model of spontaneous NIDDM.
Inheritance of rare functional GCKR variants and their contribution to triglyceride levels in families.
Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents.
Variants of Lipid-Related Genes in Adult Japanese Patients with Severe Hypertriglyceridemia.
Hypervitaminosis A
Early effects of vitamin A toxicity on hepatic glycolysis in rat.
Hypoglycemia
A novel glucokinase activator TMG-123 causes long-lasting hypoglycemia and impairs spermatogenesis irreversibly in rats.
Adaptation of glucokinase gene expression in the rat dorsal vagal complex in a model for recurrent intermediate insulin-induced hypoglycemia: impact of gender.
Brain glucosamine boosts protective glucoprivic feeding.
Cell-specific roles of glucokinase in glucose homeostasis.
Characterization of Glucokinase Catalysis from a Pseudo-Dimeric View.
Conformational transition pathway in the activation process of allosteric glucokinase.
Conformational transition pathway in the allosteric process of human glucokinase.
Counterregulatory responses to hypoglycemia in patients with glucokinase gene mutations.
Differential regulation of glucokinase activity in pancreatic islets and liver of the rat.
Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia.
Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator.
Effects of caudal fourth ventricular lactate infusion on hypoglycemia-associated MCT2, GLUT3, GLUT4, GCK, and sulfonylurea receptor-1 gene expression in the ovariectomized female rat LHA and VMH: impact of estradiol.
Effects of caudal hindbrain lactate infusion on insulin-induced hypoglycemia and neuronal substrate transporter glucokinase and sulfonylurea receptor-1 gene expression in the ovariectomized female rat dorsal vagal complex: Impact of estradiol.
Evidence-based tailoring of bioinformatics approaches to optimize methods that predict the effects of nonsynonymous amino acid substitutions in glucokinase.
Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism due to glucokinase activating mutations.
Fructose amplifies counterregulatory responses to hypoglycemia in humans.
GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?
Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy.
Glucokinase activation induces potent hypoglycemia without recruiting insulin and inhibits food intake in chicken.
Glucokinase Activators AZD6370 and AZD1656 Do Not Affect the Central Counterregulatory Response to Hypoglycemia in Healthy Males.
Glucokinase mutation-a rare cause of recurrent hypoglycemia in adults: a case report and literature review.
Glucokinase regulates reproductive function, glucocorticoid secretion, food intake, and hypothalamic gene expression.
Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study.
Hyperinsulinemic hypoglycemia subtype glucokinase V91L mutant induces necrosis in ?-cells via ATP depletion.
Hyperinsulinemic hypoglycemia without insulinoma: Think of activating glucokinase mutation.
Hyperinsulinism of the newborn.
Hypoglycemic potential of current and emerging pharmacotherapies in type 2 diabetes mellitus.
Impact of recurring intermediate insulin-induced hypoglycemia on hypothalamic paraventricular corticotropin-releasing hormone, oxytocin, vasopressin and glucokinase gene profiles: role of type II glucocorticoid receptors.
Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations.
Insights into the role of neuronal glucokinase.
Lys169 of human glucokinase is a determinant for glucose phosphorylation: implication for the atomic mechanism of glucokinase catalysis.
Molecular reductions in glucokinase activity increase counter-regulatory responses to hypoglycemia in mice and humans with diabetes.
Opposite clinical phenotypes of glucokinase disease: Description of a novel activating mutation and contiguous inactivating mutations in human glucokinase (GCK) gene.
Quantitative RT-PCR and immunoblot analyses reveal acclimated A2 noradrenergic neuron substrate fuel transporter, glucokinase, phospho-AMPK, and dopamine-?-hydroxylase responses to hypoglycemia.
Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects.
Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation.
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-concept.
Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes.
Structural model of human glucokinase in complex with glucose and ATP: implications for the mutants that cause hypo- and hyperglycemia.
SUMOylation of Pancreatic Glucokinase Regulates Its Cellular Stability and Activity.
Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator.
The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats.
The novel use of a heterozygous knockout mouse for embryofetal development assessment of a glucokinase activator.
The Relationship of Glucokinase Activator-induced Hypoglycemia with Arteriopathy, Neuronal Necrosis, and Peripheral Neuropathy in Nonclinical Studies.
The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy.
The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes.
Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia.
Ventromedial hypothalamic glucokinase is an important mediator of the counterregulatory response to insulin-induced hypoglycemia.
Hypothyroidism
Induction of oxidative stress, suppression of glucose-induced insulin release, ATP production, glucokinase activity, and histomorphometric changes in pancreatic islets of hypothyroid rat.
The Possible Mechanisms of the Impaired Insulin Secretion in Hypothyroid Rats.
Infections
A Mechanistic Probe into the Dual Inhibition of T. cruzi Glucokinase and Hexokinase in Chagas Disease Treatment - A Stone Killing Two Birds?
Glucose phosphorylation is required for Mycobacterium tuberculosis persistence in mice.
Insulin Resistance
A dominant role for glucose in beta cell compensation of insulin resistance.
A glucokinase gene mutation in a young boy with diabetes mellitus, hyperinsulinemia, and insulin resistance.
Agonist: the case for insulin resistance as a necessary and sufficient cause of type II diabetes mellitus.
Anti?diabetic effects of the ethanol extract of a functional formula diet in mice fed with a fructose/fat?rich combination diet
Arrestin domain-containing 3 (Arrdc3) modulates insulin action and glucose metabolism in liver.
Assessment of insulin sensitivity in glucokinase-deficient subjects.
Beneficial effects of Aronia melanocarpa berry extract on hepatic insulin resistance in type 2 diabetes mellitus rats.
Chronic ethanol consumption inhibits glucokinase transcriptional activity by Atf3 and triggers metabolic syndrome in vivo.
Chronic Glucocorticoid-Rich Milieu and Liver Dysfunction.
Chronically increased glucose uptake by adipose tissue leads to lactate production and improved insulin sensitivity rather than obesity in the mouse.
Dairy Product Consumption Interacts with Glucokinase (GCK) Gene Polymorphisms Associated with Insulin Resistance.
Development and regulation of glucose transporter and hexokinase expression in rat.
Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet.
Evaluation of 90-day Repeated Dose Oral Toxicity, Glycometabolism, Learning and Memory Ability, and Related Enzyme of Chromium Malate Supplementation in Sprague-Dawley Rats.
Evaluation of the Reproductive Toxicity, Glycometabolism, Glycometabolism-Related Enzyme Levels and Lipid Metabolism of Chromium Malate Supplementation in Sprague-Dawley Rats.
Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect.
F0 maternal BPA exposure induced glucose intolerance of F2 generation through DNA methylation change in Gck.
Free fatty acids increase basal hepatic glucose production and induce hepatic insulin resistance at different sites.
G/A Polymorphism at -258 of the Hepatic Glucokinase Promoter Is Not Associated with Decreased Birth Weight in Preterm Neonates.
Genetics of non-insulin-dependent (type-II) diabetes mellitus.
Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance.
Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease.
Glucokinase regulatory protein genetic variant interacts with omega-3 PUFA to influence insulin resistance and inflammation in metabolic syndrome.
Glucose potentiation of arginine-induced insulin secretion is impaired in subjects with a glucokinase Glu256Lys mutation.
Hepatic glucokinase promoter polymorphism is associated with hepatic insulin resistance in Asian Indians.
Hepatic insulin resistance induced by chronic hindlimb ischemia.
High prevalence of glucokinase mutations in Italian children with MODY. Influence on glucose tolerance, first-phase insulin response, insulin sensitivity and BMI. Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetes (SIEDP).
Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects.
Insulin Resistance Exacerbates Genetic Predisposition to Nonalcoholic Fatty Liver Disease in Individuals Without Diabetes.
Islet adaptive changes to fructose-induced insulin resistance: beta-cell mass, glucokinase, glucose metabolism, and insulin secretion.
Lessons from transgenic and knockout animals about noninsulin-dependent diabetes mellitus.
Long term liver specific glucokinase gene defect induced diabetic cardiomyopathy by up regulating NADPH oxidase and down regulating insulin receptor and p-AMPK.
Long-term follow-up of oral glucose tolerance test-derived glucose tolerance and insulin secretion and insulin sensitivity indexes in subjects with glucokinase mutations (MODY2).
Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance.
Low-Frequency Genetic Variant in the Hepatic Glucokinase Gene Is Associated With Type 2 Diabetes and Insulin Resistance in Chinese Population.
Maturity-onset diabetes of the young.
Mechanism of compensatory hyperinsulinemia in normoglycemic insulin-resistant spontaneously hypertensive rats. Augmented enzymatic activity of glucokinase in beta-cells.
Metabolic Features of Nonalcoholic Fatty Liver (NAFL) in Obese Adolescents: Findings From a Multiethnic Cohort.
Metabolic syndrome: evidences for a personalized nutrition.
Metabolomic and genetic associations with insulin resistance in pregnancy.
New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Normal Glucose Metabolism in Carnivores Overlaps with Diabetes Pathology in Non-Carnivores.
PEPCK1 Antisense Oligonucleotide Prevents Adiposity and Impairs Hepatic Glycogen Synthesis in High-Fat Male Fed Rats.
Phosphoenolpyruvate carboxykinase overexpression selectively attenuates insulin signaling and hepatic insulin sensitivity in transgenic mice.
Prevention of obesity and insulin resistance by glucokinase expression in skeletal muscle of transgenic mice.
Rare Sugar Syrup Containing d-Allulose but Not High-Fructose Corn Syrup Maintains Glucose Tolerance and Insulin Sensitivity Partly via Hepatic Glucokinase Translocation in Wistar Rats.
Relationship between regional hepatic glucose metabolism and regional distribution of hepatic fat.
Role of common sequence variants in insulin secretion in familial type 2 diabetic kindreds: the sulfonylurea receptor, glucokinase, and hepatocyte nuclear factor 1alpha genes.
Role of glucose-6 phosphatase, glucokinase, and glucose-6 phosphate in liver insulin resistance and its correction by metformin.
The metabolic response to a high-fat diet reveals obesity-prone and -resistant phenotypes in mice with distinct mRNA-seq transcriptome profiles.
Therapeutic potential of NaoXinTong Capsule on the developed diabetic nephropathy in db/db mice.
Vitamins and their derivatives in the prevention and treatment of metabolic syndrome diseases (diabetes).
[Glucokinase gene mutations in gestational diabetes in Polish population. Prediction of diabetes mellitus development after delivery]
[Insulin and physical exercise]
Insulinoma
Acute glucose intolerance in insulinoma cells with unbalanced overexpression of glucokinase.
Adult-onset hyperinsulinaemic hypoglycaemia in clinical practice: diagnosis, aetiology and management.
An alternate promoter in the glucokinase gene is active in the pancreatic beta cell.
Characteristics of glucokinase of the Kirkman insulinoma.
Discrimination of glucose anomers by glucokinase from liver and transplantable insulinoma.
Effect of retinoic acid on glucokinase activity and gene expression and on insulin secretion in primary cultures of pancreatic islets.
Evaluation of the expression of hexokinase 1, glucokinase, and insulin by canine insulinoma cells maintained in short-term culture.
Glucagon-like peptide 1 stimulates post-translational activation of glucokinase in pancreatic beta cells.
Glucokinase and glucokinase regulatory protein: mutual dependence for nuclear localization.
Glucokinase gene structure. Functional implications of molecular genetic studies.
GLUT-2 gene transfer into insulinoma cells confers both low and high affinity glucose-stimulated insulin release. Relationship to glucokinase activity.
Hexokinase isoenzymes of RIN-m5F insulinoma cells. Expression of glucokinase gene in insulin-producing cells.
Hyperinsulinemic hypoglycemia without insulinoma: Think of activating glucokinase mutation.
Identification and significance of glucokinase in transplantable insulinomas.
Identification of glucokinase as an alloxan-sensitive glucose sensor of the pancreatic beta-cell.
Insulin secretion, insulin content and glucose phosphorylation in RINm5F insulinoma cells after transfection with human GLUT2 glucose-transporter cDNA.
Mannose phosphorylation by glucokinase from liver and transplantable insulinoma. Cooperativity and discrimination of anomers.
Modulation of glucose responsiveness of insulinoma beta-cells by graded overexpression of glucokinase.
Multiple elements in the upstream glucokinase promoter contribute to transcription in insulinoma cells.
Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1)
Novel insulinoma cell lines produced by iterative engineering of GLUT2, glucokinase, and human insulin expression.
Prolactin induction of insulin gene expression: the roles of glucose and glucose transporter-2.
Regulation of insulin secretion from novel engineered insulinoma cell lines.
Ischemic Attack, Transient
Ischemic preconditioning maintains the immunoreactivities of glucokinase and glucokinase regulatory protein in neurons of the gerbil hippocampal CA1 region following transient cerebral ischemia.
Time-course changes in immunoreactivities of glucokinase and glucokinase regulatory protein in the gerbil hippocampus following transient cerebral ischemia.
Ischemic Stroke
Functional Variants of Glucokinase Regulatory Protein and Apolipoprotein A5 Genes in Ischemic Stroke.
Polymorphisms in the GCKR are associated with serum lipid traits, the risk of coronary artery disease and ischemic stroke.
Ketosis
The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes.
Latent Autoimmune Diabetes in Adults
Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.
Leishmaniasis
The crystal structure of glucokinase from Leishmania braziliensis.
Lipidoses
Discovery of piragliatin-first glucokinase activator studied in type 2 diabetic patients.
Liver Cirrhosis
Correction: glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic Fatty liver disease.
Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic Fatty liver disease.
Hexokinase isoenzymes in normal and cirrhotic human liver: suppression of glucokinase in cirrhosis.
Liver Cirrhosis, Biliary
Reduced hepatic glycogen stores in patients with liver cirrhosis.
Liver Diseases
A Rare Nonsense Mutation in the Glucokinase Regulator Gene Is Associated With a Rapidly Progressive Clinical Form of Nonalcoholic Steatohepatitis.
Association of GCKR Gene Polymorphisms with the Risk of Nonalcoholic Fatty Liver Disease and Coronary Artery Disease in a Chinese Northern Han Population.
Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene.
Association of rs780094 polymorphism of glucokinase regulatory protein with non-alcoholic fatty liver disease.
Common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: a meta-analysis.
Contribution of Rs780094 and Rs1260326 Polymorphisms in GCKR Gene to Nonalcoholic Fatty Liver Disease: A Meta-Analysis Involving 26,552 Participants.
Control of liver glucokinase activity: A potential new target for incretin hormones?
Correction: glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic Fatty liver disease.
Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals.
Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease.
Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic Fatty liver disease.
Hexokinase isoenzymes in normal and cirrhotic human liver: suppression of glucokinase in cirrhosis.
Hormonal and Metabolite Regulation of Hepatic Glucokinase.
Metabolic Features of Nonalcoholic Fatty Liver (NAFL) in Obese Adolescents: Findings From a Multiethnic Cohort.
Non-alcoholic fatty liver disease concerns with glucokinase activators - Authors' reply.
Non-alcoholic fatty liver disease concerns with glucokinase activators.
[Clinical studies on the serum glucokinase activity values. 1. Erythrocyte glucokinase activity values in normal infants and children, in ekiri-like syndrome, in diabetes mellitus, and in liver diseases.]
Lymphoma, Non-Hodgkin
Intracellular localization of glucokinase and glycolytic enzymes in lymphosarcoma.
Malnutrition
Onset of carbon catabolite repression in Aspergillus nidulans. Parallel involvement of hexokinase and glucokinase in sugar signaling.
Perinatal nutrient restriction induces long-lasting alterations in the circadian expression pattern of genes regulating food intake and energy metabolism.
Melanoma, Experimental
Proteomic study reveals a co-occurrence of gallic acid-induced apoptosis and glycolysis in B16F10 melanoma cells.
Menkes Kinky Hair Syndrome
Characterization of colorectal-cancer-related cDNA clones obtained by subtractive hybridization screening.
Metabolic Diseases
Human glucokinase gene: isolation, structural characterization, and identification of a microsatellite repeat polymorphism.
Metabolic Syndrome
Association Between a Glucokinase Regulator Genetic Variant and Metabolic Syndrome in Taiwanese Adolescents.
Chronic ethanol consumption inhibits glucokinase transcriptional activity by Atf3 and triggers metabolic syndrome in vivo.
GCKR common functional polymorphisms are associated with metabolic syndrome and its components: a 10-year retrospective cohort study in Iranian adults.
Glucokinase regulatory protein genetic variant interacts with omega-3 PUFA to influence insulin resistance and inflammation in metabolic syndrome.
Impact of Type 2 diabetes on Glucokinase diabetes (GCK-MODY) phenotype in a Roma (Gypsy) family - case report.
Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects.
Metabolic syndrome: evidences for a personalized nutrition.
Migraine Disorders
Genetic approaches to common diseases.
Multiple Endocrine Neoplasia
Thymic Carcinoid as the First Manifestation of Multiple Endocrine Neoplasia Type 1 Syndrome: A Case Report and Review of the Literature.
Multiple Endocrine Neoplasia Type 1
Thymic Carcinoid as the First Manifestation of Multiple Endocrine Neoplasia Type 1 Syndrome: A Case Report and Review of the Literature.
Myocardial Ischemia
NONRATT021972 long-noncoding RNA: A promising lncRNA in diabetes-related diseases.
Neoplasms
Adult-onset hyperinsulinaemic hypoglycaemia in clinical practice: diagnosis, aetiology and management.
Anti-Diabetic Effect of Trigonelline and Nicotinic Acid, on KK-A(y) Mice.
Anti-diabetic potential of alkaloid rich fraction from Capparis decidua on diabetic mice.
Carbohydrate metabolism in human renal clear cell carcinomas.
Cellular and molecular characterization of a feline insulinoma.
Characteristics of glucokinase of the Kirkman insulinoma.
Defective regulation of glucokinase in rat pancreatic islet cell tumours.
Differential regulation of glucokinase activity in pancreatic islets and liver of the rat.
Effect of tumors with different growth rates on enzymes in host liver.
Evaluation of the expression of hexokinase 1, glucokinase, and insulin by canine insulinoma cells maintained in short-term culture.
Evidence for a major gene for type II diabetes and linkage analyses with selected candidate genes in Mexican-Americans.
Expression of two type II-like tumor hexokinase RNA transcripts in cancer cell lines.
First evidence of changes in enzyme kinetics and stability of glucokinase affected by somatic cancer-associated variations.
Hepatoprotective Effects of Polydatin-Loaded Chitosan Nanoparticles in Diabetic Rats: Modulation of Glucose Metabolism, Oxidative Stress, and Inflammation Biomarkers.
High Km glucose-phosphorylating (glucokinase) activities in a range of tumor cell lines and inhibition of rates of tumor growth by the specific enzyme inhibitor mannoheptulose.
Hormonal and dietary regulation of hepatic enzymes in tumor-bearing rats.
Inhibitory effects of streptozotocin, tumor necrosis factor-alpha, and interleukin-1beta on glucokinase activity in pancreatic islets and gene expression of GLUT2 and glucokinase.
Synergism of ursolic acid derivative US597 with 2-deoxy-D-glucose to preferentially induce tumor cell death by dual-targeting of apoptosis and glycolysis.
Synthesis and Biological Evaluation of Novel Ursolic acid Derivatives as Potential Anticancer Prodrugs.
The association between Mediterranean Diet Score and glucokinase regulatory protein gene variation on the markers of cardiometabolic risk: an analysis in the European Prospective Investigation into Cancer (EPIC)-Norfolk study.
The effect of lymphoma and other neoplasms on hepatic and plasma enzymes of the host rat.
The glucose sensor protein glucokinase is expressed in glucagon-producing alpha-cells.
The Mechanism by Which Amentoflavone Improves Insulin Resistance in HepG2 Cells.
Thymic Carcinoid as the First Manifestation of Multiple Endocrine Neoplasia Type 1 Syndrome: A Case Report and Review of the Literature.
Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in ? cells.
UP12, a novel ursolic acid derivative with potential for targeting multiple signaling pathways in hepatocellular carcinoma.
[13C6,D8]2-deoxyglucose phosphorylation by hexokinase shows selectivity for the ?-anomer.
[Activity of the key glycolysis and respiration enzymes in the rat liver in chemical carcinogenesis]
[Hexokinase and glucokinase activity in human and animal tumors]
Neuroendocrine Tumors
Targeted oncogenesis of hormone-negative pancreatic islet progenitor cells.
Non-alcoholic Fatty Liver Disease
A novel index including SNPs for the screening of nonalcoholic fatty liver disease among elder Chinese: A population-based study.
A Rare Nonsense Mutation in the Glucokinase Regulator Gene Is Associated With a Rapidly Progressive Clinical Form of Nonalcoholic Steatohepatitis.
Association of GCKR Gene Polymorphisms with the Risk of Nonalcoholic Fatty Liver Disease and Coronary Artery Disease in a Chinese Northern Han Population.
Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene.
Association of rs780094 polymorphism of glucokinase regulatory protein with non-alcoholic fatty liver disease.
Common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: a meta-analysis.
Contribution of Rs780094 and Rs1260326 Polymorphisms in GCKR Gene to Nonalcoholic Fatty Liver Disease: A Meta-Analysis Involving 26,552 Participants.
Correction: glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic Fatty liver disease.
Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals.
Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease.
Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic Fatty liver disease.
Hormonal and Metabolite Regulation of Hepatic Glucokinase.
Metabolic Features of Nonalcoholic Fatty Liver (NAFL) in Obese Adolescents: Findings From a Multiethnic Cohort.
Natural history of NASH.
New Perspectives in Pediatric Nonalcoholic Fatty Liver Disease: Epidemiology, Genetics, Diagnosis, and Natural History.
Non-alcoholic fatty liver disease concerns with glucokinase activators - Authors' reply.
Non-alcoholic fatty liver disease concerns with glucokinase activators.
The rate of production of uric acid by hepatocytes is a sensitive index of compromised cell ATP homeostasis.
Obesity
A major quantitative trait locus determining serum leptin levels and fat mass is located on human chromosome 2.
Cafeteria diet overfeeding in young male rats impairs the adaptive response to fed/fasted conditions and increases adiposity independent of body weight.
Changes in pancreatic islet glucokinase and hexokinase activities with increasing age, obesity, and the onset of diabetes.
Clinical characteristics of subjects with a missense mutation in glucokinase.
Common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: a meta-analysis.
Constitutive hepatic glucokinase activity in db/db and ob/ob mice.
Functional glucokinase regulator gene variants have inverse effects on triglyceride and glucose levels, and decrease the risk of obesity in children.
Glucokinase Regulatory Protein (GCKR) Gene rs4425043 Polymorphism is Associated with Overweight and Obesity in Chinese Women.
Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity.
Hepatic glucokinase modulates obesity predisposition by regulating BAT thermogenesis via neural signals.
In situ glucose uptake and glucokinase activity of pancreatic islets in diabetic and obese rodents.
Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects.
Prevention of obesity and insulin resistance by glucokinase expression in skeletal muscle of transgenic mice.
Role of pregnane X receptor in obesity and glucose homeostasis in male mice.
Suboptimal maternal nutrition, during early fetal liver development, promotes lipid accumulation in the liver of obese offspring.
The -30G>A polymorphism of the glucokinase gene promoter is associated with obesity in a population from southern Spain.
[STUDY RELATIVE EXPRESSION OF GENES THAT CONTROL GLUCOSE METABOLISM IN THE LIVER IN MICE WITH DEVELOPMENT OF MELANOCORTIN OBESITY].
Obesity, Morbid
A Rare Nonsense Mutation in the Glucokinase Regulator Gene Is Associated With a Rapidly Progressive Clinical Form of Nonalcoholic Steatohepatitis.
Overweight
Glucokinase Regulatory Protein (GCKR) Gene rs4425043 Polymorphism is Associated with Overweight and Obesity in Chinese Women.
Paralysis
Acute glucose intolerance in insulinoma cells with unbalanced overexpression of glucokinase.
Peripheral Nervous System Diseases
The Relationship of Glucokinase Activator-induced Hypoglycemia with Arteriopathy, Neuronal Necrosis, and Peripheral Neuropathy in Nonclinical Studies.
Pituitary Neoplasms
Cellular characterization of pituitary adenoma cell line (AtT20 cell) transfected with insulin, glucose transporter type 2 (GLUT2) and glucokinase genes: insulin secretion in response to physiological concentrations of glucose.
D-glucose transport and utilization in pituitary adenoma cells transfected with glucokinase gene.
Prediabetic State
10-year trajectory of ?-cell function and insulin sensitivity in the development of type 2 diabetes: a community-based prospective cohort study.
Characterization of hepatic glucose metabolism disorder with the progress of diabetes in male Spontaneously Diabetic Torii rats.
Production of a mouse strain with impaired glucose tolerance by systemic heterozygous knockout of the glucokinase gene and its feasibility as a prediabetes model.
Prostatic Neoplasms
A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study).
Protein Deficiency
The expression of growth-arrest genes in the liver and kidney of the protein-restricted rat fetus.
Psoriasis
[The skin activity of hexokinase, glucokinase and phosphofructokinase in psoriasis patients]
Renal Insufficiency, Chronic
Effect of Hepatic Organic Anion-Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver-Targeted Glucokinase Activator: A Model-Based Evaluation.
Variants of GCKR Affect Both {beta}-Cell and Kidney Function in Patients With Newly Diagnosed Type 2 Diabetes: The Verona Newly Diagnosed Type 2 Diabetes Study 2.
Situs Inversus
Novel deletion mutation in the glucokinase gene from a korean man with GCK-MODY phenotype and situs inversus.
Starvation
Adaptation of glycolytic enzymes: glucose use and insulin release in rat pancreatic islets during fasting and refeeding.
Apparent starvation-induced repression of pancreatic islet glucokinase.
Effect of different thyroid states on rat liver glucokinase synthesis and degradation in vivo.
Effect of thyroid hormones on glucokinase gene transcription in rat liver.
Effects of succinic acid dimethyl ester infusion on metabolic, hormonal, and enzymatic variables in starved rats.
Hepatic glucokinase turnover in intact and adrenalectomized rats in vivo.
Loss of adaptive mechanisms during aging.
Molecular cloning of hepatic glucose-6-phosphatase catalytic subunit from gilthead sea bream (Sparus aurata): response of its mRNA levels and glucokinase expression to refeeding and diet composition.
Nutrient-dependent distribution of insulin and glucokinase immunoreactivities in rat pancreatic beta cells.
Protective action of succinic acid monomethyl ester against the impairment of glucose-stimulated insulin release caused by glucopenia or starvation: metabolic determinants.
Rapid action of insulin and cyclic AMP in the regulation of functional messenger RNA coding for glucokinase in rat liver.
Reciprocal distribution of hexokinase and glucokinase in the periportal and perivenous zone of the rat liver acinus.
Regulation of glucokinase and GLUT-2 glucose-transporter gene expression in pancreatic B-cells.
Species and tissue distribution of the regulatory protein of glucokinase.
Zonal expression of the glucokinase gene in rat liver. Dynamics during the daily feeding rhythm and starvation-refeeding cycle demonstrated by in situ hybridization.
Transfusion Reaction
[Glucokinase activity of the myocardium, skeletal muscles, kidneys and bone marrow in transfusion reactions in dogs]
Tuberculosis
Cg2091 encodes a polyphosphate/ATP-dependent glucokinase of Corynebacterium glutamicum.
Involvement of tryptophan(s) at the active site of polyphosphate/ATP glucokinase from Mycobacterium tuberculosis.
Purification of polyphosphate and ATP glucose phosphotransferase from Mycobacterium tuberculosis H37Ra: evidence that poly(P) and ATP glucokinase activities are catalyzed by the same enzyme.
Whooping Cough
Bordetella pertussis extract induces increase in the activities of glycolytic enzymes in mouse liver.